The Prediction of Preterm Birth by Bonney, Elizabeth Anne
 
 













Submitted in accordance with the requirements 





The University of Leeds 
 





The candidate confirms that the work submitted is her own and that appropriate 
credit has been given where reference has been made to the work of others. 
 
This copy has been supplied on the understanding that it is copyright material 
and that no quotation from the thesis may be published without proper 
acknowledgement. 
 
The right of Elizabeth Anne Bonney to be identified as Author of this work has 
been asserted by her in accordance with the Copyright, Designs and Patents 
Act 1988. 
 
© 2015 The University of Leeds and Elizabeth Anne Bonney 
 iii 
Acknowledgements 
Dr Nigel Simpson, Dr Jenny Myers and Professor James Walker have provided 
guidance, encouragement and support over the years leading to the completion 
of this thesis. They have been instrumental in focusing my interest in research 
and I shall be forever grateful to them. Nigel, in particular, has been influential in 
developing my interest into the prevention of prematurity and provided the 
inspiration to continue questioning the causes and pathways leading to preterm 
birth. Alongside this thesis, he has been a role model to whom I aspire and 
taught me the importance of excellent clinical care. He has taught me clinical 
and surgical skills to help the women who experience such devastating 
outcomes following mid trimester loss or preterm birth. I shall forever be 
indebted to him.   
I am grateful to the international collaborators and research teams who brought 
together the SCOPE biobank which was the source of the clinical and biological 
data used in this thesis. I am particularly grateful to the women who were 
recruited to the SCOPE study. Their willingness to participate in research in 
their first pregnancy, to try and help other women who have experienced 
problems, has been humbling.  
This research would not have been possible without the collaboration and 
interactions with Professor Robyn North and Professor Mik Black in Auckland, 
New Zealand who provided valuable support with the data processing and 
variable reductions in Chapter 2. My collaboration with the Maternal and Fetal 
Health Research Centre in Manchester provided me with a fantastic opportunity 
to work in a large and successful research department. Dr Richard Blankley, in 
particular, supported me in the difficult but exciting field of proteomics and 
taught me all the technical skills used in Chapter 3. The Leeds Perinatal 
Research Group, and in particular Dr Nicolas Orsi, has provided immense 
guidance and knowledge in the role of cytokines for Chapter 4. His input, along 
with that of Dr Tathagata Dasgupta from Harvard Medical School, was 
invaluable. 
Finally, I thank my family, especially my parents Susan and Douglas and sister 
Charlotte, who have supported me on this journey. They have taught me to 




Preterm birth is a persistent and expensive global health problem accounting for 
almost 8% of all live births in the UK. There are some effective interventions 
available however, due to the heterogeneous nature of the condition; it is still 
difficult to tailor the correct management for each woman. A major obstacle to 
the development of effective treatment strategies is a limited understanding of 
the molecular events preceding preterm labour. Using SCOPE, a prospectively 
acquired global cohort, this MD investigated the three areas of clinical risk 
factors, biomarker discovery using proteomic technology and directed candidate 
cytokine analysis. 
 
Clinical risk factor algorithms have been developed with the most clinically 
relevant group, those delivering less than 34 weeks, exhibiting the best 
predictive performance. The algorithm has an area under the ROC curve of 
0.74, negative predictive value of 99%, with a positive predictive value of 33%. 
This is likely to be indicative of the best performance achievable using clinical 
data to predict preterm birth in a healthy nulliparous population. 
 
A proteomic discovery study was performed comparing term and preterm birth. 
The proteins that were discovered appeared to be mainly plasma proteins 
related to systemic inflammation and therefore were not specific enough as 
predictors of spontaneous preterm birth.  
 
As there is strong evidence to support a role for cytokines in the initiation of 
inflammation/infection-induced preterm labour, a panel of 27 were assessed as 
predictive markers for preterm birth. Of these, five cytokines (IL-4, IFN-γ, IL-6, 
IL-17α and MIP-1α) appeared to be the most sensitive with a predictive 
accuracy of 71.25%.  
 
The data from this thesis have provided further understanding into preterm birth 
and provides a pathway for future investigation into the prediction and 
prevention of spontaneous preterm birth.  
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1.1 Preterm birth 
1.1.1 Definition and rates  
Preterm birth is defined as a delivery that occurs before 37 completed weeks (or 
less than 259 days) of gestation. It is a persistent and expensive global health 
problem. The World Health Organisation estimated the incidence to be 9.6% in 
2005, equating to approximately 12.9 million preterm births worldwide each year 
(1). A review in 2012 reported that this had increased to 14.9 million (11.1%) in 
2010 (Figure  1.1) (2). 
 





In countries where robust data exist, preterm birth continues to be a significant 
adverse outcome of pregnancy. The preterm birth rate has risen in most 
industrialised countries, with the incidence in the USA increasing from 9.5% in 
1981 to 12.8% in 2006 (Figure  1.2). 
 
Figure ‎1.2 Preterm birth rates (%), USA 1998-2008 (3) 
 
 
The rising trend seen in the United States of America has been mirrored in 
other countries such as Scotland, Australia, and Denmark (4-6). This is despite 
advancing knowledge of risk factors and mechanisms related to preterm labour, 
and the introduction of many public health and medical interventions designed 
to reduce preterm birth. Whilst there have been improvements in antenatal and 
neonatal care, the number of premature babies born each year has not 
significantly decreased since the 1960s (7). The United Kingdom has only 
recently started to collect data on preterm birth, in 2005 it was estimated to be 
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1.1.2 Morbidity and mortality 
In developed countries, preterm birth accounts for 75% of perinatal mortality (9) 
and the earlier the gestation at birth, the higher the rate of mortality. In 2005 in 
England and Wales, there were 947 deaths per 1,000 live births at 22 weeks 
compared with 1.3 deaths per 1,000 live births among babies born at 40 weeks 
gestational age (Figure  1.3) (8). 
 
Figure ‎1.3 Infant mortality rate by gestational age in England and Wales in 
2005. Early neonatal, before 7 days of age; late neonatal at least 7 but under 28 days of 








Preterm birth is also the precursor of significant short- and long-term morbidity 
(see Table  1-1) (9). Children born preterm have higher rates of learning 
disabilities, cerebral palsy, sensory deficits and respiratory illness compared to 
children born at term. 
 
Table ‎1-1 Complications and disabilities related to prematurity (10) 
Neonatal Short term Long term 
Respiratory distress 
syndrome (RDS) 





Infection Sensory deficits 
Periventricular 
leukomalacia (PVL) 








Patent ductus arteriosus 
(PDA) 
Retinopathy Difficulties at school 
Infection Transient dystonia Behavioural problems 
Metabolic abnormalities  Chronic lung disease 
Nutritional deficiencies   
 
These negative health and developmental effects of preterm birth often extend 
into later life, resulting in significant medical, educational, psychological and 
social costs (11-14). Estimates indicate that within the USA, the costs in terms 
of medical and educational expenditure and lost productivity associated with 
preterm birth were more than US$26.2 billion in 2005 (15). The Epicure study 
(12, 16) in the UK studied outcomes for children born before 26 weeks gestation 
in 1995. The overall survival to discharge from hospital was 39%, rising from 
20% at 23 completed weeks to 52% at 25 completed weeks. Between 54% and 
75% of the population assessed at the age of six years were functioning in the 
normal range, or had mild disability that did not prevent them from being 
independent. The study was repeated in 2006 (17), with data showing that the 
outcomes had improved for those babies born after 24 and 25 weeks gestation 
in this cohort, with 34% of children having no problems at follow up at 3 years of 
age compared with 23% in the 1995 cohort. However, at earlier gestations, 
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despite the number of babies being admitted for care rising by 44%, the number 
of children surviving with severe disability had also risen in the 2006 cohort. 
 
1.1.3 Types/precursors of preterm birth 
Preterm birth can be subdivided according to gestational age (Figure  1.4): about 
5% of preterm births occur at less than 28 weeks (extreme prematurity), about 
15% between 28–31 weeks (severe prematurity), around 20% between 32–33 
weeks (moderate prematurity), and 60–70% beyond 34 weeks (late prematurity) 
(18). 
 
 Figure ‎1.4 Types of preterm birth (18)   
 
 
Alternatively, it may be classified according to factors governing birth. In this 
way about 30-35% of preterm births are indicated, which means delivery for 
maternal or fetal indications, in which labour is either induced or the infant is 
delivered by prelabour caesarean section. The remainder of deliveries are 
regarded as spontaneous, referring to preterm birth with intact membranes (40-
45%) or that consequent upon preterm prelabour rupture of the membranes 
(PPROM) (25-30%), irrespective of whether delivery is vaginal or by caesarean 










membranes at less than 37 weeks’ gestation at least one hour before the onset 
of contractions with risk factors generally similar to those for spontaneous 
preterm labour. Most women with PPROM begin labour spontaneously within 
several days, but a small proportion of women remain undelivered for weeks or 
months. Since the membranes generally form a barrier to ascending infection, a 
common complication of PPROM is the development of intrauterine infection 
and preterm labour (20). 
 
Figure ‎1.5 Precursors of preterm birth (adapted from (18)) 
 
 
Much of the increase in the singleton preterm birth rate has been attributed to 
rising numbers of indicated late preterm births (21). The higher number of 
preterm multiple gestations associated with assisted reproductive technologies 
is an important contributor to the overall increase in preterm births in this group; 
however, even singleton pregnancies following in-vitro fertilisation are at 
increased risk of preterm birth (22). Accurate estimation of preterm birth rates 
and their proper characterisation (e.g. spontaneous or indicated) is essential for 
accurate determination of global incidence in order to determine and implement 





Delivery for maternal or fetal
indications





1.1.4 Causes of preterm birth 
A major obstacle to the development of effective treatment strategies for 
preterm labour is a limited understanding of the molecular events required to 
initiate and maintain term and preterm labour. The common manifestations of 
term and preterm parturition include increased myometrial contractility, cervical 
ripening (dilatation and effacement) and decidual/membrane activation. Romero 
et al.(23) proposed the term ‘Preterm Parturition Syndrome’ in view of the 
combination of signs and/or symptoms that form a distinct clinical picture 
indicative of premature parturition. Preterm labour is now thought to be initiated 
by multiple mechanisms, including local and systemic infection or inflammation, 
placental factors, uterine factors and cervical factors (Figure  1.6). 
 





1.1.4.1 Local and Systemic Infection 
Intrauterine colonisation and concomitant infection/inflammation has emerged 
as a major pathogenic mechanism to explain preterm birth. Histopathologic and 
microbiological studies suggest that infection may account for 25-40% of 
preterm birth (25). Furthermore, the earlier the delivery, the higher the 
frequency of intrauterine infection (25, 26). Inflammatory infiltration of the fetal 
membranes and/or maternal decidua in early preterm labour provokes a large 
increase in prostaglandin output by these tissues, which may trigger delivery 
(27). There is evidence to support this causal link from animal studies, where 
intrauterine infection or the systemic administration of microbial products results 
in spontaneous preterm birth (28-30). The most common microbial isolates from 
women with preterm labour are Ureaplasma urealyticum, Fusobacterium 
species and Mycoplasma hominis (31). 
 
Microorganisms may gain access to the uterine cavity and fetus by ascending 
from the vagina and cervix, through haematogenous dissemination through the 
placenta, through retrograde seeding from the peritoneal cavity via the fallopian 
tube, or by accidental introduction at the time of invasive procedures such as 
amniocentesis. The most common pathway for intrauterine colonisation is the 
ascending route from the lower genital tract to the choriodecidual space and 
subsequently to the amniotic cavity and fetus (23). It is believed that term 
delivery is associated with an endocrine-mediated local inflammatory process 
leading to the release of uterotonic agents (32), in the course of an ascending 
infection, this inflammatory cascade may be prematurely activated. 
Microorganisms produce enzymes such as proteases and mucinases, which 
weaken the cervical mucus plug barrier and allow further ascent of bacteria. 
Bacteria also release phospholipases, which promote the formation of 
arachidonic acid, from which prostaglandins are produced. Prostaglandins have 
a fundamental role in contraction of the smooth muscle of the uterus and the 
biophysical changes associated with cervical ripening. Bacteria also release 
endotoxins, which cause a release of proinflammatory cytokines such as 
interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor (TNF). The 
proinflammatory cytokines in turn stimulate the expression of enzymes in the 
prostaglandin biosynthetic pathway. Microorganisms also enhance the 
production of matrix metalloproteinases, leading to the breakdown of the fetal 
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membranes, ripening of the cervix and uterine contractions (23). Antibiotic 
treatment of ascending uterine infections can prevent preterm birth in 
experimental models for chorioamnionitis (33). 
 
Bacterial vaginosis (BV) is a disorder defined by a change in the microbial 
ecosystem of the vagina. It is diagnosed clinically by the presence of clue cells, 
a vaginal pH greater than 4.5, a profuse white discharge, and a fishy odour 
when the vaginal discharge is exposed to potassium hydroxide. In the 
laboratory, BV is defined by the Nugent criteria in which Gram-stained smears 
are scored on the basis of numbers of lactobacilli, which tend to be low, and the 
presence of organisms resembling Gardnerella, Mycoplasma, Mobiluncus and 
Bacteroides, the numbers of which tend to be high. A score of 7–10 is used to 
diagnose BV, and has been associated with a 1.5-fold to 3-fold increase in the 
rate of preterm birth (34, 35). Black women in both the USA and the UK are 
three times more likely to have BV than are white women, and this difference 
might in part explain 50% of the excess preterm births in black women (36, 37). 
The mechanisms by which bacterial vaginosis is associated with preterm birth 
are unknown. 
 
It was initially thought that prophylactic antibiotics for the prevention of preterm 
birth in women at risk may have no effect on the preterm birth rate (38). 
However, a more recent metaanalysis (39) of randomized clinical trials showed 
that when clindamycin is administered to pregnant women with evidence of BV 
before 22 weeks of gestation the rate of PTB before 37 weeks of gestation and 
spontaneous late miscarriage is significantly lower than in the control group. 
The reduction in the risk of PTB before 37 weeks of gestation was only 
statistically significant for oral clindamycin but not for vaginal clindamycin. 
 
Extrauterine infections such as malaria (40) and pyelonephritis (41, 42) have 
also been associated with preterm birth and treatment of asymptomatic 
bacteriuria has been shown to reduce low birth weight but has conflicting 




Periodontal disease (45-48) may allow organisms within gingival crevices to 
cause a maternal bacteraemia and transplacental passage of bacteria, resulting 
in an intrauterine infection. Oral bacteria has been demonstrated to be present 
in the amniotic fluid of women who develop preterm birth and/or low birth weight 
(49).The biological pathways underlying the relationship between periodontal 
disease and preterm birth remains elusive. 
 
1.1.4.2 Placental factors and haemorrhage 
Evidence to support that poor placentation, consequent upon defective 
remodelling of spiral arteries leading to their atherosis or thrombosis, may 
cause preterm birth is increasing. Arias et al. (50) reported vascular lesions in 
decidual vessels attached to the placenta in 34% of women in spontaneous 
preterm labour, in 35% of those with PPROM, and in only 12% of control 
women with term pregnancies. Placental abruption is more frequent in women 
who deliver preterm than those who deliver at term (50). Women who develop 
spontaneous preterm birth have a higher percentage of failure of physiological 
transformation in the myometrial segment of the spiral arteries than women who 
deliver at term (51, 52). It has also been shown that the frequency of small-for-
gestational-age infants is increased in women who have spontaneous preterm 
birth (53, 54). The precise mechanisms for the onset of preterm labour in 
women with uteroplacental ischaemia are unknown. 
 
Vaginal bleeding caused by placental abruption or placenta praevia is 
associated with a very high risk of preterm delivery, but bleeding in the first and 
second trimesters that is not associated with abruption or praevia is also related 
to subsequent preterm birth (55). The risk factors for placental abruption include 
maternal cigarette smoking and cocaine use, chronic hypertension and pre-
eclampsia, maternal trauma, IUGR, and hereditary coagulopathies. Each of 
these conditions is associated with damage to the spiral arteries and the 
bleeding is closely related to thrombin generation. Thrombin acts to stimulate 
coagulation and clot formation; however, it also stimulates the production of 
proteases capable of ripening the cervix and damaging fetal membranes, 
leading to PPROM. Thrombin may also exert an indirect uterotonic effect on the 
myometrium and stimulate contractions (56). 
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1.1.4.3 Uterine factors 
Women with Mullerian duct variants (57-59), polyhydramnios (60) and multiple 
pregnancy (23) are at increased risk of preterm birth. Nahum (61) established 
that uterine abnormalities are found in 1 in 201 (0.5%) of the general female 
population. The distribution was 7% arcuate, 34% septate, 39% bicornuate, 
11% didelphic, 5% unicornuate and 4% hypoplastic/aplastic/solid and other 
forms. A systematic review by Chan et al. in 2011 (62), suggested that there 
was no significant increased risk of preterm birth in women with arcuate uteri, 
often considered an incidental benign finding. There was however, a significant 
increased risk with canalization defects (RR 2.14; 95% CI, 1.48-3.11; P<0.001), 
more specifically, subseptate (RR, 2.01; 95% CI, 1.16-3.51; P=0.01), and 
septate uteri (RR, 2.30; 95% CI, 1.46-3.62; P<0.001). Whilst the exact aetiology 
is unknown, it has been suggested that the endometrium overlying the septum 
is abnormal and therefore a poor site for implantation (63-65). Unification 
defects, such as the bicornuate, unicornuate and didelphic uterus (RR, 2.97; 
95% CI, 2-08-4.23; P<0.001) also showed significantly increased risks of 
preterm birth. 
 
Intraamniotic pressure remains relatively stable throughout gestation despite 
the growing fetus and placenta (66, 67). This has been attributed to progressive 
myometrial relaxation due to the effects of progesterone and endogenous 
myometrial relaxants such as nitric oxide. However, accelerated stretching due 
to polyhydramnios or multiple pregnancy can induce increased myometrial 
contractility, prostaglandin release and upregulate oxytocin receptors in the 
myometrium. The effect of stretch increases in late gestation and is maximal 
during labour due to reduction of uterine stretch and decrease in concentrations 
of progesterone (23). 
 
1.1.4.4 Cervical factors 
The spectrum of consequences manifest in cervical-related pathology includes 
recurrent pregnancy loss in the mid-trimester, varying presentations of preterm 
labour (i.e. presenting with bulging membranes with no apparent uterine 
activity), and probably precipitate labour at term. Cervical disease may be the 
result of a congenital disorder (e.g. DES exposure in utero), surgical trauma 
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(e.g. cone biopsy or LLETZ/LEEP procedures), or traumatic damage to the 
integrity of the cervix (e.g. multiple dilations of the cervix). 
 
In low-risk women, cervical length is a normally-distributed variable with a mean 
of 35-40mm from 14 to 30 weeks. The lower 10th percentile is 25mm. A 
progressive shortening is noticed after 30 weeks (68). Studies (68-70) in 
asymptomatic singleton pregnancies demonstrated that the shorter the cervical 
length, the higher the risk of preterm birth (Figure  1.7). However, in the low risk 
population the sensitivity is low, with 82% of women found to have a short 
cervical length at 24 weeks delivering at or after 35 weeks (68). 
 
In contrast, cervical length is a good predictor in women at high risk, such as 
those who have had a previous preterm birth (71). The sensitivity is around 60-
80% and a positive predictive value of 70% can be obtained when a cervical 
length of less than 25mm is seen between 14 and 18 weeks (72). Conversely, 
high-risk patients with a normal cervical measurement between 14 and 18 
weeks only have a 4% risk of delivering preterm. The presence of internal os 
collapse (funnelling) (73) and of amniotic fluid particulate matter (’sludge’) (74) 
increases the risk of preterm birth and chorioamnionitis. After 30 weeks of 
gestation, the cervix progressively shortens physiologically in preparation for 
labour and as a result, it is not recommended to rely on cervical length 
measurement at this gestation and beyond for the prediction of spontaneous 





Figure ‎1.7 Risk‎ of‎ spontaneous‎ delivery‎ at‎ ≤‎ 32‎ weeks‎ according‎ to‎
cervical length at 23 weeks of gestation (70) 
 
 
History of cervical cone biopsy or loop electrocautery excision procedures 
(LEEP) secondary to premalignant cervical disorders have also been 
associated with an increase in spontaneous preterm birth (75, 76). A recent 
systematic review (77) demonstrated this increased risk (RR 2.19, 95% CI 1.93-
2.49), with cold knife cone biopsy (RR 3.41, 95% CI 2.38-4.88) and laser 
conisation (3.58, 95% CI 1.93-6.61) being more pronounced than LEEP (RR 
1.85, 95% CI 1.59-2.15). Repeat LEEP procedures increase the risk almost 
five-fold (RR 5.15, 95% CI 2.45-7.84) (75) and increasing depth of excised 
tissue further increases risk, with an estimated 6% increase in risk for each 
additional millimetre (OR 1.06, 95% CI 1.03-1.09) (78). There is increasing 
evidence that the presence of CIN itself (even without treatment) is associated 
with an increased risk of preterm birth, perhaps through shared risk factors for 
preterm birth (79-81). In most cases it will be the combination of pathological 
processes, such as cervical disease and infection, which will cause the preterm 
birth. Intrauterine infection has been shown to be present in nearly 50% of 
women with acute cervical insufficiency (82).  
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A history of one induced termination of pregnancy is associated with an 
increased risk of spontaneous preterm birth (OR 1.36, 95% CI 1.24-1.50), which 
increases as the number of terminations increases (OR 1.93, 95% CI 1.28-2.71) 
(83). Suspected mechanisms causing spontaneous preterm birth in this 
scenario include alterations of the cervical immunological environment; the 
cervicovaginal flora and the host antimicrobial response to ascending infection; 
mechanical trauma to the cervix; and scarring following repeated dilatation and 
curettage resulting in altered tissue quality. Interestingly, a recent paper has 
speculated that recently the risk may have lessened in preterm birth following 
termination of pregnancy, and that this may be due to a change in termination 
practice such as increasing use of medical abortion and cervical pre-treatment 
prior to surgical termination (84).  
 
1.1.5 Clinical risk factors 
Precise mechanisms cannot always be established, therefore risk factors 
associated with preterm birth have been sought to explain or predict preterm 
birth. An increasing number of risk factors are thought to interact to cause a 
transition from uterine quiescence towards preterm labour or PPROM. As 
preterm birth is a heterogeneous condition, it is very likely that several different 
clinical (11-14) and biochemical (85, 86) parameters confer an increased risk. 
 
Defining risk factors for the prediction of preterm birth is a reasonable goal for 
several reasons. First, identification of an at-risk woman allows initiation of risk-
specific treatment (87). Second, the risk factors might define a population useful 
for studying specific interventions. Finally, identification of risk factors might 
provide important insights into mechanisms leading to preterm birth. 
 
1.1.5.1 Previous pregnancy history 
Previous preterm labour and delivery is the most significant risk factor for 
preterm birth (88, 89). This association is modified by three factors: the 
frequency of prior preterm deliveries, the gestational age at which the previous 
birth occurred, and the order in which the prior preterm birth occurred (90). The 
incidence of subsequent recurrent spontaneous preterm birth is increased 
twofold in women with a history of one spontaneous preterm birth (91, 92). 
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McManemy et al. (Figure  1.8) demonstrated that the recurrence risk ranged 
from 42% in women with two prior preterm births, down to 21% (term/preterm), 
13% (preterm/term), and 5% (term/term). The recurrence risk was highest 
(57%) for women with two prior very preterm deliveries (21-31 weeks) and 
lowest (33%) for those with two prior moderate preterm deliveries (32-36 
weeks) (90). 
 





In the UK and USA, women classified as black, African-American, and Afro-
Caribbean are consistently reported to be at higher risk of preterm delivery: 
preterm rates are in the range 16-18% in black women compared with 5-9% for 
white women. Black women are also three or four times more likely to have an 
extreme preterm birth than women from other racial or ethnic groups (93, 94). 
Furthermore the causes of preterm birth differ by ethnic group. Preterm birth is 
most commonly preceded by preterm labour in white women, whereas PPROM 

























preterm birth rates between black and white women has remained largely 
unchanged and unexplained, and contributes to a cycle of reproductive 
disadvantage with far-reaching social and medical consequences (95). East 
Asian and Hispanic women typically have lower preterm birth rates. Women 
from South Asia, including the Indian subcontinent, may have higher rates of 
low birth weight caused by decreased fetal growth, but preterm delivery does 
not seem to be substantially increased. Other maternal demographic 
characteristics associated with preterm birth include low socioeconomic and 
educational status, low and high maternal age, and single marital status (96-
98). The mechanisms by which these maternal demographic characteristics are 
related to preterm birth are unknown. Few population based studies have 
looked at the immigration effect of pregnancy outcome. Friedman et al (99) 
found that infants delivered to Caribbean-born black mothers had a significantly 
lower low birth rate (LBW) rate than did infants delivered to US-born black 
mothers. A further study (100) looking at the women of Illinois supported these 
findings. This suggests secondary social factors such as social evaluative threat 
may play a significant role in adverse pregnancy outcome. 
 
1.1.5.3 Low socioeconomic status 
Socioeconomic status (SES) (98, 101-104) is generally used to define social 
inequality, and is usually measured by income and/or educational attainment. 
Education is the dimension of SES that most strongly and consistently predicts 
health (104). A low level of education limits a person’s access to jobs and other 
social resources, which in turn limits his/her capacity to integrate within society 
and thereby increases the risk of subsequent poverty. Socio-economic 
disadvantage is unlikely to be a direct, independent determinant of preterm 
birth; instead, it probably leads to unhealthy lifestyle choices, exposure to 
stress, and psychological reactions to stress that shorten gestation (105). 
 
As discussed previously, the potential role of genital tract colonisation, infection 
and inflammation has been identified as a cause of preterm birth (26, 34, 106-
109). BV is more common among the socially disadvantaged (34, 110), and it 
therefore seems reasonable to speculate that a genital tract infection could be 
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an important mediating variable in explaining the high risk of preterm birth 
among the socially disadvantaged. 
 
It has been shown that women living in low SES areas experience more 
stressful life events during their pregnancy and the chronic stressors often result 
from the environment they live in (101, 111-113). These include financial 
insecurities, poor and crowded housing conditions, living without a partner, 
unsatisfying marital relationships, domestic violence, and stressful working 
conditions (101, 114, 115). They also often have a more restricted social 
support network (116) which is often less available during their pregnancy which 
can increase the impact of those stressors. 
 
1.1.5.4 Stress 
Mothers experiencing high levels of psychological or social stress are at an 
increased risk of preterm birth even after adjustment for the effects of 
sociodemographic, medical, and behavioural risk factors (117, 118). 
Furthermore, exposure to objectively stressful conditions, such as housing 
instability and severe material hardship, has also been associated with preterm 
birth (119). Fetal stress may be due to problems in placental function. 
 
Although the mechanism underlying the association between psychological or 
social stress and increased risk of preterm birth is unknown, a role for 
corticotrophin-releasing hormone (CRH) has been proposed. CRH mediates 
pituitary adrenocorticotropin (ACTH) secretion in both the maternal and fetal 
pathways, which in turn increases maternal and fetal cortisol secretion. 
Increased cortisol levels rapidly increase the amount of circulating CRH. These 
elevated CRH levels induce prostaglandin production (120-122). Prostaglandins 
cause contractions, cervical ripening and sensitise the myometrium to oxytocin. 
CRH also enhances placental oestrogen production by stimulating the secretion 
of its precursor from the fetal adrenal gland. Oestrogens interact with the 




Women exposed to stressful conditions also have increased serum 
concentrations of inflammatory markers, such as C-reactive protein; an 
observation not accounted for by other established risk factors for inflammation 
(123).  These findings suggest that systemic inflammation might be a pathway 
by which stress could increase the risk of preterm birth. 
 
1.1.5.5 Nutritional status/BMI 
Nutritional status during pregnancy can be quantified by assessments of body 
size such as body mass index (BMI), nutritional intake, and serum assessments 
of various analytes (124-126). A low pre-pregnancy BMI is associated with a 
high risk of preterm birth, whereas moderate obesity can be protective (126). 
Women with low serum concentrations of iron, folate, or zinc have more preterm 
births than those with measurements in the normal range (124, 127). There are 
many potential mechanisms by which maternal nutritional status might affect 
preterm birth.  
 
1.1.5.6 Smoking 
Tobacco use increases the risk of preterm birth (<2-fold) after adjustment for 
other factors (128-130). The mechanisms by which smoking is related to 
preterm birth are unclear. There are more than 3000 chemicals in cigarette 
smoke and the biological effects of most are unknown (131); however, both 
nicotine and carbon monoxide are powerful vasoconstrictors, and are 
associated with placental damage and decreased uteroplacental blood flow. 
Both of these pathways lead to fetal growth restriction and indicated preterm 
births, however, interestingly, smoking reduces the risk of developing pre-
eclampsia, another cause of indicated preterm birth (132). Smoking is 
associated with a systemic inflammatory response and may increase 
spontaneous preterm birth through that pathway (133, 134). 
 
1.1.5.7 Interpregnancy interval 
Both short and long interpregnancy intervals have been associated with an 
increased risk of adverse perinatal outcomes (135). Smith et al.(136) found an 
interpregnancy interval of less than 6 months conferred a greater than two-fold 
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increased risk of preterm birth after adjustment for maternal age, marital status, 
height, socioeconomic deprivation, smoking, previous birth weight and previous 
caesarean section. The association was specific to preterm birth and neonatal 
death, as no association existed between a short interpregnancy interval and 
the risk of delivering a growth-restricted infant. 
 
1.1.5.8 Multiple Pregnancy 
Multiple gestations account for only 2-3% of all infants, but they carry a 
substantial risk of preterm delivery, and so account for 15-20% of all preterm 
births. Nearly 60% of twins are born preterm. About 40% of twins will 
spontaneously labour or rupture their membranes before 37 weeks, with others 
requiring an indicated preterm delivery because of preeclampsia, or other 
maternal or fetal complications (18). Nearly all higher multiple gestations will 
result in preterm delivery. Uterine overdistension, resulting in contractions and 
PPROM, is believed to be one of the causative mechanisms for the rate of 
increased spontaneous preterm births (23). 
 
1.1.5.9 Familial risk factors 
A study in Norway has shown that mothers who themselves were born preterm 
had a significantly increased risk of having preterm offspring (137). This 
followed a dose-response pattern such that increasing severity of prematurity 
was associated with an increasing risk of preterm birth in their offspring. 
Compared with 6.4% of index women born at term having preterm offspring, the 
incidence of having preterm offspring was 14.0% among women who had been 
born at 22 to 27 weeks, 9.2% for those born at 28 to 32 weeks, and 8.8% for 
those born at 33 to 36 weeks (137). Porter et al.(138) also established that a 
woman who herself was delivered preterm was more likely to suffer 
spontaneous preterm labour and preterm birth, and it has been demonstrated 
that mothers with an older sister who had given birth to a preterm infant also 





1.1.6 Why are nulliparous women so important? 
In low risk nulliparous women the most pertinent clinical risk indicator, that of a 
previous preterm delivery, is not applicable and therefore in routine clinical 
practice we have no means of identifying which healthy nulliparous women will 
later deliver preterm. A test which would allow a proportion of these women to 
be identified as high risk in mid gestation would allow a targeted programme of 
cervical surveillance and the potential for prophylactic treatments such as 
progesterone (140-142).  
 
Development of a successful predictive test for PTB will probably require the 
combined assessment of multiple biochemical, clinical and biophysical risk 
factors. To date, this strategy has not been possible due to the necessity for a 
large pregnancy biobank of appropriate samples collected, in conjunction with 
detailed pregnancy metadata. The recent creation of unique pregnancy 
biobanks such as SCOPE (Screening for Pregnancy Endpoints - 
www.medscinet.net/scope) have now made this work achievable. Furthermore, 
recent advances in analytical techniques have resulted in technologies capable 
of quantifying multiple analytes simultaneously. As a consequence studies of 
the proteome, genome, and metabolome are now feasible which themselves 
may offer further insights into the multiplicity of pathways which lead to preterm 
birth.  
 
1.1.7 Why Screen? 
The World Health Organisation produced guidelines detailing the principles of a 
screening test in 1968 (143). These guidelines are still applicable today and 
preterm birth fulfils some of the WHO criteria for screening. It is an important 
health problem for the individual and the community; screening would probably 
be economically balanced in relation to possible expenditure on medical care as 
a whole; there is evidence that treatment started at an early stage would be of 
more benefit than treatment started later. There are, however, some aspects 
which are still lacking: the natural history of the disease is not yet adequately 
understood, there is no universally accepted treatment or useful intervention for 
patients with the disease, and a suitable and acceptable screening test or 
examination is not yet established. 
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1.1.8 Traditional methods of screening 
The traditional methods of screening are based on a range of epidemiological 
risk factors such as previous preterm birth, maternal age, race and smoking 
status. Several risk scoring systems have been developed. The most commonly 
evaluated scoring system is the Creasy score (144, 145), which was developed 
by ascribing a numerical value to individual risk factors and by weighting risk 
factors differently depending on their importance. This predictive method, 
however, lacks sufficient sensitivity and specificity for routine clinical use. Most 
women who deliver preterm are not identified by the risk-scoring system and the 
majority of women identified as high risk will not deliver preterm. Furthermore, 
because a traditional risk factor score is based largely on previous obstetric 
history, its accuracy is particularly poor among women expecting their first child, 
who comprise half of those affected by PTB. A systematic review (145) showed 
a lack of studies evaluating clinically important outcomes such as birth before 
34 weeks’ gestation, and suggested there is a need for better quality 
information about accuracy of risk scoring systems.  
 
1.1.9 Screening of symptomatic women 
The symptoms associated with preterm labour are often varied and non-
specific. Of patients who present with symptoms of preterm labour (i.e., uterine 
contractions), 50-80% will deliver at term without any intervention (146, 147). It 
is therefore important for the clinician to be able to distinguish between non-
specific abdominal pain or uterine activity and true preterm labour. This will 
prevent unnecessary admission and treatment of patients who are not at risk of 
premature delivery. Once a woman presenting with symptoms has been 
highlighted as being at risk of preterm birth, with signs such as cervical 
dilatation, it is often too late to make a significant difference. Tocolysis can be 
administered to allow administration of corticosteroids, to improve lung 
maturation, and to permit transfer to a facility with an appropriate neonatal unit, 
however, there is no evidence it will prolong pregnancy in any other way which 
will improve outcome (148-150). Non-invasive tests are commercially available 
to identify those women at greatest risk of preterm birth and include 
cervicovaginal fetal fibronectin (fFN) and phosphorylated insulin-like growth 
factor binding protein-1 (phIGFBP-1). 
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1.1.9.1 Fetal Fibronectin  
Fetal fibronectin (fFN) is a glycoprotein found in the amniotic fluid, placental 
tissue, and the extracellular component of the decidua basalis adjacent to the 
placental intervillous space. It should not normally be present in cervicovaginal 
fluids between 22 and 35 weeks, however, it may be released after mechanical- 
or inflammatory-mediated damage to the membranes or placenta before birth 
and therefore may be present in women at risk of preterm birth (151). 
Cervicovaginal fluid fFN has a negative predictive value of approximately 99% 
for predicting delivery in symptomatic women within 2 weeks of testing (147, 
152). Positive prediction, however, is modest (<20%), and because most 
women have a good outcome, many are overtreated (147). The current 
qualitative test (Rapid fFN TLIIQ; Hologic, Marlborough, MA) provides a positive 
or negative result based on a threshold of 50ng/mL (153).  
 
Studies that have used enzyme-linked immunosorbent assay (ELISA)-based 
quantification of fFN suggest that concentrations of fFN within cervicovaginal 
secretions correlate with the risk of spontaneous preterm birth. Knowledge of 
the fFN concentration appears to improve prediction and this is now 
commercially available as a bedside test (Hologic 10Q system, Hologic, 
Marlborough, MA) (154, 155). This bedside test has been evaluated in a recent 
study of 300 patients which demonstrated that the quantitative information adds 
further value to the qualitative test (156).  
 
1.1.9.2 Actim Partus (phIGFBP-1) 
Insulin-like growth factor is a protein synthesised by the liver and is involved in 
the control of fetal growth and development. Its binding protein (IGFBP-1) is 
found in different forms and the phosphorylation status varies in different body 
fluids and tissues (157, 158). The non-phosphorylated isoform predominates in 
amniotic fluid and its detection in cervical and vaginal samples is diagnostic of 
membrane rupture (159). The highly phosphorylated isoform (phIGFBP-1), 
which is produced by the decidua, is not present in the amniotic fluid, but may 
be an indicator of tissue damage at the choriodecidual interface. During the 
events preceding labour, fetal membranes start to detach from the decidua and 
phIGFBP-1 leaks into cervical secretions (160). A bedside kit called Actim 
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Partus (Alere, UK) has been developed for the detection of phIGFBP-1 in these 
secretions. One of the largest studies (301 women) has calculated the 
sensitivity, specificity, PPV and NPV to be 69.2%, 90.5%, 50% and 95.5% 
respectively for delivery before 37 weeks’ gestation in symptomatic women 
(160). 
 
1.1.9.3 Transvaginal ultrasound of the cervix 
Transvaginal scanning of the cervix in women who are symptomatic of preterm 
labour may also help to detect those who will deliver preterm. Unfortunately, the 
availability of equipment and skills needed to perform a TVS are not commonly 
found on a labour ward in the United Kingdom. Several studies have found that 
the shortening of the uterine cervix as assessed by transvaginal sonography 
had sensitivity ranging between 73–100% and specificity between 44–94% for 
symptomatic patients (161-163). Most importantly, it has an excellent NPV of 
about 80%, meaning that it can identify a group of women who are at low risk 
for preterm delivery, allowing a reduction in the number of tocolytic treatments. 
According to Iams et al. (163), a canal length >30 mm indicates that significant 
effacement has not occurred and the likelihood of preterm birth is low. 
 
1.1.10 Screening of asymptomatic women 
Identifying women at high risk of preterm birth before their symptoms appear 
would allow initiation of early and targeted interventions to try and modify the 
outcome. At present there is no commercial test to fulfil that need. An ideal 
predictive tool for preterm birth would identify women who present with various 
subtypes of the same condition (i.e. preterm birth attributable to several different 
aetiologies). 
 
1.1.10.1 Transvaginal ultrasound of the cervix 
The most accurate and reproducible method of cervical evaluation is 
transvaginal ultrasound, and cervical length assessment is an established 
predictor for preterm birth. Data indicates that the shorter the cervical length, 
the higher the risk of spontaneous preterm birth (164). As a result, cervical 
length measurement is currently the gold standard for prediction of spontaneous 
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preterm birth in the high risk population. Table  1-2 illustrates the predictive 
ability of cervical length measurement in identifying those who will deliver 
spontaneously preterm.  
 
In low risk women, the mean cervical length at 14-30 weeks of gestation is 35-
40mm, with the lower 10th percentile being 25mm and the upper 10th percentile 
being 50mm (68). Prior to 14 weeks of gestation, it is less easy to define the 
cervical length. After 30 weeks, cervical length measurement is not 
recommended as the cervix progressively shortens physiologically in 
preparation for labour. An ultrasound-indicated cerclage in the low risk 
population does not seem to prevent PTB (165, 166) therefore it is not 
recommended that cervical length is used as a routine screening predictor of 
PTB in low-risk women.  
 
Cervical length assessment is most sensitive in screening singleton 
pregnancies with a previous preterm birth, as over two-thirds of women 
destined to deliver preterm can be detected early whilst asymptomatic (167). 
Additionally, sensitivity remains over 50% in singleton pregnancies with other 
risk factors for preterm birth, such as a previous cone biopsy (168), Mullerian 
anomaly (58) or previous multiple dilatations and curettage (169).  
 
Despite all these data, there still remains a lack of understanding regarding the 
association between cervical length and spontaneous preterm birth and this is 
demonstrated by the fact that some women with a short cervix will have a 
preterm birth, whilst others will have uncomplicated term deliveries (164). 
Ideally, determining the risk status of a woman would be done in early 
pregnancy to allow appropriate targeted antenatal care. However, accurate 
prediction of symptomatic and asymptomatic women in later pregnancy is 
equally important in order to guide the administration of antenatal 
corticosteroids for fetal lung maturation, which is of greatest benefit in the first 
week following administration (149), hospital admission and appropriate transfer 
to neonatal facilities. Whilst TVS of the cervix may aid this the newer prediction 




 Table ‎1-2 Prediction of preterm birth in singletons by cervical length. (Adapted from (170)) 
 n PTB (%) Primary 
outcome 
(GA) 
GA CL Sens Spec PPV NPV RR 
Low risk (68) 
 




183 26 <35 16-24 25 69 80 55 88 4.4 
Prior LEEP (168) 
 












64 11 <35 14-23+6 25 71 91 50 95 13.5 
PTB, preterm birth; GA, gestational age in weeks; CL, cervical length; Sens, sensitivity; Spec, specificity; PPV, positive 
predictive value; NPV, negative predictive value; RR’ relative risk; LEEP, loop electrical excision procedure; D&C, dilatation 
and curettage.  
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1.1.10.2 Biochemical markers 
1.1.10.2.1  Fetal fibronectin 
Although the use of fFN for identifying symptomatic women at risk of preterm 
labour is now widely accepted, the role of fFN in high risk asymptomatic women 
has been less clear (85, 171). This is mainly due to the limited specificity and 
positive predictive value of the qualitative bedside test, however, the newer 
quantitative test appears to improve its predictive performance (154, 172). A 
recent study (172) of fFN levels taken at 24 weeks in asymptomatic women with 
a prior preterm birth demonstrated that as the fibronectin concentrations 
increased, the risk of spontaneous preterm birth became progressively greater 
(Table  1-3). The numbers in this study were small however, so these findings 
need to be confirmed in larger studies. 
 
Table ‎1-3 Relative risk of spontaneous preterm delivery by fetal 
fibronectin level (relative to fetal fibronectin = 0ng/mL) (taken from 
(172)) 
 sPTD <28wk 
RR (95% CI) 
sPTD <32 wk 
RR (95% CI) 
sPTD <34wk 
RR (95% CI) 
sPTD <37wk 
RR (95% CI) 


























1.1.10.2.2  Other predictive markers 
Although many candidate-driven approaches to studying biomarkers have 
shown promise, this has not resulted in the identification of predictive PTB 
biomarkers for the general pregnant population. A recent systematic review by 
Conde-Aguedelo et al (173) investigated the accuracy of novel biomarkers to 
predict spontaneous preterm birth in women with singleton pregnancies and no 
symptoms of preterm labour. Table  1-4 shows the range of novel biomarkers for 
the prediction of preterm birth identified in the literature. 
 
None of the biomarkers evaluated met the criteria to be considered a clinically 
useful test to predict spontaneous preterm birth. This could be due to bias in the 
methodology as the majority of studies are involving small numbers and 
investigate specific populations rather than a range of women from different 
backgrounds. This along with the complex heterogeneity of preterm birth may 




Table ‎1-4 Novel biomarkers for the prediction of the spontaneous preterm 
birth phenotype identified in the literature (taken from (173)) 
1. Inflammation-related biomarkers 
Interleukins-2, -6, -8 and -10 
Tumour necrosis factor-α 
Granulocyte colony–stimulating factor 
Stromal cell-derived factor-1α 
Interferon-γ 
Matrix metalloproteinase-8 
A disintegrin and metalloproteinase-8 and -12 
Elastase 
Secretory leukocyte proteinase inhibitor 
Soluble vascular cell adhesion molecule-1 




2. Placental proteins/hormone-related biomarkers 
Human chorionic gonadotropin 
Phosphorylated insulin-like growth factor binding protein-1 
Prolactin 
Relaxin 
Pregnancy-associated plasma protein A 
Placental protein 13 
Activin A 
Pregnancy-specific β-1-glycoprotein 
3. Angiogenesis-related biomarkers 
Angiogenin 
Soluble endoglin 
4. Coagulation-related biomarkers 
Thrombin-antithrombin III complex 









1.1.11 Prevention of preterm birth 
Many proposed interventions to prevent delivery or delay and improve neonatal 
outcome remain unsatisfactory or unproven. Strategies to reduce morbidity and 
mortality in infants born preterm have been limited to the administration of 
antenatal corticosteroids for fetal lung maturation and advances in neonatal 
intensive care (149). Repeated corticosteroid doses are no longer common 
practice following randomised controlled trials which have shown alterations in 
fetal growth and impaired neurodevelopment outcomes without long term 
benefit on pulmonary function (174, 175). However a recent Cochrane 
Systematic Review (176) has now refuted this claim and suggested that repeat 
doses of glucocorticoids should be considered in women at risk of preterm birth 
seven or more days after an initial course, in view of the neonatal benefits. 
 
1.1.11.1 Traditional recommendations 
Bed rest in home or hospital has been widely recommended in the past for the 
prevention of preterm birth. This advice is based on the observation that hard 
work and physical activity during pregnancy could be associated with preterm 
birth and that bed rest could reduce uterine activity. There is however, no 
evidence, either supportive or refuting, for the use of bed rest to prevent 
preterm birth, however, jobs requiring heavy lifting/upright posture have been 
shown to be associated with preterm birth (177, 178). This has even been 
demonstrated in women with a short cervix (179). When women are offered bed 
rest, there are many potential adverse effects on women and their families and, 
increased costs for the healthcare system (180). 
 
1.1.11.2 Cervical Cerclage 
The traditional intervention for women with recurrent preterm deliveries or 
second trimester losses is cervical cerclage. Although reported by Shirodkar 
(181) in 1955, cervical cerclage remains one of the more controversial surgical 
interventions in obstetrics (182). Its use has expanded to include the 
management of women with other risk factors of preterm birth, such as multiple 
pregnancy, uterine anomalies, a history of cervical trauma (e.g. cone biopsy) 
and cervical shortening on ultrasound examination. The use in these differing 
groups is highly controversial. Whist cerclage may provide a degree of 
structural support to a ‘weak’ cervix; its more important role may be in 
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maintaining the cervical length and the endocervical mucus plug as a 
mechanical barrier to ascending infection. 
 
Cervical cerclage is not without risk. Reported adverse events shortly after 
suture insertion include abdominal pain, vaginal bleeding, PPROM and bladder 
injury. Late complications can include infections such as chorioamnionitis or 
miscarriage. 
 
Three different categories of patients who may benefit from cerclage can be 
defined. History-indicated or elective cerclage is performed on women with a 
recurrent history of mid-trimester loss or early preterm birth. The second 
category is ultrasound-indicated or emergent cerclage, that is performed on 
asymptomatic women where ultrasound examination reveals a short cervix with 
or without collapse of the internal os (also known as ‘funnelling’). The third is 
rescue cerclage, where there are clear signs of cervical dilatation and significant 
effacement with exposed fetal membranes at the external cervical os or within 
the vagina but with no uterine contractions. 
 
Although there is little evidence as to the efficacy of elective cervical cerclage, it 
is widely accepted practice (183). A large trial comparing history-indicated 
cerclage with expectant management (184) showed there were fewer deliveries 
before 33 weeks gestation in the cerclage group compared with controls (13% v 
17%; RR 0.75; 95% CI 0.58-0.98). There were no significant differences 
between the two groups in fetal/neonatal outcome. In the subgroup analyses, 
only women who had had a history of three or more pregnancies ending before 
37 weeks benefited from cerclage (delivery before 33 weeks 15% v 32%, 
P<0.05). 
 
When the history is less conclusive, some clinicians choose to insert a cervical 
cerclage only when a short cervix is found on ultrasound (164, 166, 183, 185). 
An RCT (186) reporting on women with a history of spontaneous preterm birth 
between 17+0 and 33+6 weeks gestation who were found to have a cervix 
<25mm on ultrasound scan, demonstrated that when cerclage was compared to 
expectant management, it led to a reduction in preterm birth <24 weeks 
gestation (6.1% v 14%; P=0.03), but did not prevent birth <35 weeks gestation 
(32% v 42%; OR 0.67, 95% CI 0.42-1.07) unless the cervical length was less 
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than 15mm (OR 0.23; 95% CI 0.08-0.66). Table  1-5 illustrates evidence on the 
use of cerclage for prevention of spontaneous preterm birth in women with a 
short cervix. 
 
Rescue cerclage has a success rate of approximately 50% (187-189) and is 
employed after careful consideration due to the extremely poor prognosis once 
fetal membranes are visible. The evidence for benefit is not substantial as there 
are a lack of controlled trials in this area. Nonetheless, under ideal conditions, 
rescue cerclage may significantly prolong pregnancy and increase the likelihood 
of a viable pregnancy outcome (187, 190, 191). As sub-clinical infection is likely 
to be implicated in the aetiology of bulging membranes, some clinicians will 
perform amniocentesis prior to cerclage insertion to exclude infection (192). 
 
To et al (165) screened low risk women using transvaginal ultrasound to 
measure cervical length between 22-24 weeks gestation. Women who had a 
cervix of 15mm or less were randomised to cerclage or expectant management. 
There was no difference in the number of preterm deliveries between these 
groups (22% v 26%; RR 0.84; 95% CI 0.54-1.3, P=0.44). Other studies have 
since confirmed this and it is therefore not standard practice to insert cerclage 
into low risk women with a cervix of 25mm or less. (166) The Royal College of 
Obstetricians and Gynaecologists green-top guideline suggests insertion of a 
cerclage after 3 or more preterm births/mid-trimester losses or when the cervix 

















Cerclage type Primary 
outcome 
Relative risk PTB <35 
weeks (95% CI) 
Relative risk PTB <35 
weeks in singletons 
with prior PTB 16-36 
weeks (95% CI) 
 






16-24 <25 McDonald PTB<34 
weeks 












14-27 <25 McDonald PTB<34 
weeks 
0.98 (0.69-1.39) 0.75 (0.40-1.40) 
To et al. 
 (2004)(165) 
All singletons 44/253  
(17) 
22-24 ≤15 Shirodkar PTB<33 
weeks 
 










14-24 <25 McDonald PTB<35 
weeks 
0.76 (0.51-1.15) 0.68 (0.27-1.77) 
Owen et al. 
(2009) (186) 
All singletons 
with a prior 




16-22+6 <25 McDonald PTB<35 
weeks 
0.67 (0.42-1.07) 0.67 (0.42-1.07) 





Progesterone has been administered for the prevention of preterm birth for 
many years. The first trial using progesterone for the prevention of preterm birth 
in women at increased risk was published in 1970 (197). The exact 
mechanism/s by which progesterone confers benefit is/are not fully understood 
but it is thought to be essential for pregnancy maintenance (198). It is 
postulated to maintain myometrial quiescence, inhibit cervical ripening, increase 
the efficacy of the cervical mucus barrier, and decrease the production of 
proinflammatory cytokines which are thought to be key to decidual/membrane 
activation (199, 200). This has in part been challenged by Sexton et al (201) as 
their study suggested that the benefits of 17-alpha hydroxyprogesterone 
caproate (17P) for preterm labour prevention are not achieved, even partially, 
by a direct utero-relaxant effect (in vitro, on myometrial strips). They postulated 
that their findings opened the possibility that genomic effects of 17P, achieved 
over long periods of administration, are required for its reported therapeutic 
benefits. 
 
It is known that inhibition of progesterone action can result in parturition for 
example, administration of a progesterone antagonist (RU486, Mifepristone) to 
pregnant women, can induce labour (198). In many species, a fall in serum 
progesterone concentration occurs prior to spontaneous parturition, however 
this has not been demonstrated in humans (202). 
 
Randomised clinical trials indicate that progesterone administration to women 
with a previous preterm birth reduces the rate of spontaneous preterm birth 
(140, 141, 203). A Cochrane meta-analysis assessing the benefits and harms of 
progesterone during pregnancy to prevent spontaneous preterm birth showed 
that progesterone is associated with a reduction in risk of spontaneous preterm 
birth before 37 weeks (RR 0.65, 95% CI 0.54-0.79), and infant birth weight 
under 2500g (RR 0.63, 95% CI 0.49-0.81)(204). 
 
The optimal dosage, mode of administration and duration of use remains 
unanswered. The two main forms of progesterone currently being used in the 
UK are intramuscular injections of 17-alpha hydroxyprogesterone caproate 





Table ‎1-6 Characteristics of RCTs of progesterone for the prevention of spontaneous preterm birth 
Study Population screened 
 




(1970)(205)   
‘High preterm risk 
score’ 
99 Intramuscular 17P 
(250mg every 3 
days) vs placebo 
from 28-32 weeks of 
gestation 
PTB<37 weeks Progesterone (2/50) 
vs placebo (2/49); 
OR 0.24 (95% CI 
0.07-0.82) 
Johnson et al. (1975) 
(206) 
Prior PTB 50 Intramuscular 17P 
(250mg weekly) vs 
placebo from 
‘booking’ until 24 
weeks of gestation 
PTB<37 weeks Progesterone (2/18) 
vs placebo (12/25): 
OR 0.19 (95% CI 
0.05-0.70) 
Hartikainen-Sorri et 
al. (1975) (207) 
Multiple pregnancy 77 Intramuscular 17P 
(250mg weekly) vs 
placebo from 28 
until 37 weeks 
gestation 
Perinatal death Progesterone (4/78) 
vs placebo (2/76): 
OR 1.94 (95% CI 
0.38-9.87) 
Hauth et al. (1983) 
(208) 




168 Intramuscular 17P 
(1000mg weekly) vs 
placebo from 16 to 
20 weeks until 36 
weeks of gestation 
 
 
Preterm labour Progesterone (5/80) 
vs (placebo (5/88): 





Study Population screened Population (n) Intervention Primary outcome Results of primary 
outcome 
Da Fonseca et al. 
(2003) (140) 
Prior PTB, presence 





(100mg daily) vs 
placebo from 24 to 
28 weeks of 
gestation 
PTB<37 weeks and 
<34 weeks 
Progesterone 13.8% 
vs placebo 28.5% 
(p<0.05) for PTB <37 
weeks and 2.7% vs 
18.5% (p<0.05) for 
PTB <34 weeks 




463 Intramuscular 17P 
(250mg) vs placebo 
(castor oil) from 16-
20 weeks until 36 
weeks 
PTB<37 weeks Progesterone 36.3% 
vs placebo (54.9%): 
RR 0.66 (95% CI 
0.54-0.81) 
Facchinetti et al. 
(2007)  (209) 
Presented  in TPTL 




use of tocolytics  
60 Intramuscular 17P 
(341mg every 4 
days) vs placebo 
until 36 weeks 
gestation 
Cervical length by 
ultrasound 
17P: reduction of 
risk of PTB (OR 0.15; 
95% CI 0.04-0.58) 
Fonseca et al. (2007) 
(142) 






(200mg daily) vs 
placebo from 24 




vs placebo 34.4%; RR 
0.56 (95% CI 0.36-
0.86) 






daily) vs placebo 
Spontaneous PTB 
<34 weeks 
Progesterone 10% vs 
placebo 11.3%; OR 





Study Population screened 
 
Population (n) Intervention Primary outcome Results of primary 
outcome 
Rouse et al. (2007) 
(211)  
Multiple pregnancy 661 Intramuscular 17P 
(250mg weekly) vs 
placebo (castor oil) 
from 16-20+3 weeks 
gestation until 34 
weeks gestation 
Composite of death 
or delivery <35 
weeks 
Progesterone 41.5% 
vs placebo 37.3%; RR 
1.1 (95% CI 0.9-1.3) 
Borna and Sahabi 
(2008) (212) 
Women presenting 
in TPTL between 24 
and 34 weeks 
gestation, in whom 
acute symptoms 
arrested following 
use of tocolytics 
70 Vaginal 
progesterone 





longer mean latency 
until delivery (36.1 ± 
17.9 vs 24.5 ± 27.2) 
(mean ± SD) days 
(p=0.03) 
Norman et al. (2009) 
(213) 
Twin pregnancy 500 Vaginal 
progesterone gel 
(90mg daily) vs 
placebo gel from 24 
until 34 weeks 
gestation 
PTB or IUD <34 
weeks gestation 
24.7% (61/247) in 
the progesterone 
group and 19.4% in 
the placebo group; 
OR 1.36 (95% CI 
0.89-2.09) (p=0.16) 
Caritis et al. (2009) 
(214) 
Triplet pregnancy 134 Intramuscular 17P 
(250mg weekly) vs 
placebo starting at 
16-20 weeks and 
continued until 35 
weeks gestation 
Composite of 
delivery or fetal loss 
<35 weeks of 
gestation 
Similar in both 
groups: 83% 17P vs 
84% placebo; RR 1.0 




Study Population screened Population (n) Intervention Primary outcome Results of primary 
outcome 




81 Intramuscular 17P 
(250mg weekly) vs 
placebo starting at 
16-22 weeks and 




Similar in 17P and 
placebo groups (38% 
vs 41%; p=0.71) 
Berghella et al. 
(2010) (203) 
Prior SPTB (17-33+6 
weeks gestation) 





300 Intramuscular 17P 
(250mg weekly) 
starting from 16-22+6  
after randomisation 
to cerclage or no 
cerclage for a short 
cervix on ultrasound  
PTB<35 weeks 17P had no effect in 
either cerclage 
(p=0.64) or no 
cerclage (p=0.51) 
groups; OR 0.80 
(95% CI 0.40-1.58) 
Hassan et al. (2011) 
(216) 
Singleton pregnancy 
with short cervix 
(10-20mm) at 19 to 




(90mg daily) vs 
placebo gel from 20-
23+6 weeks until 36+6 
weeks gestation 
PTB<33 weeks 8.9% (21/235) in the 
progesterone group 
and 16.1% (36/223) 
in the placebo 
group; RR 0.55 (95% 
CI 0.33-0.92)(p=0.02) 
Grobman et al. 
(2012) (217) 




16 and 22+3 
657 Intramuscular 17P 
(250mg weekly) or 
placebo from 16-
22+3 until 36 weeks 
PTB <37 weeks 25.1% in the 
progesterone group 
vs 24.2% in placebo 
group; RR 1.03 (95% 
CI 0.79-1.35) 
PTB, preterm birth; 17P, 17-alpha hydroxyprogesterone caproate; OR, odds ratio; RR relative risk; CI confidence interval; IUD, 




The use of antibiotics in asymptomatic high-risk women is controversial. A 
Cochrane review (218) showed there was little evidence that screening and 
treating all pregnant women with asymptomatic bacterial vaginosis prevented 
spontaneous preterm birth. However, in women with a previous preterm birth, 
treatment of bacterial vaginosis may reduce the risk of PPROM and low 
birthweight. A meta-analysis by Simcox et al. (38) failed to show benefit and 
suggested that treating women at risk of spontaneous preterm birth with 
antibiotics did not reduce their risk of subsequent preterm birth. Conversely, the 
use of metronidazole in asymptomatic high-risk women appears to increase the 
risk of spontaneous preterm labour (219, 220), possibly due to changes in 
vaginal flora (221). As a result it is suggested that clindamycin, either oral (222) 
or vaginal (223), may be the better treatment choice for symptomatic bacterial 
vaginosis. 
 
In view of the infection/inflammation link to preterm birth, many studies have 
looked at the use of antibiotics for the treatment of women with symptoms 
suggestive of preterm labour (224). ORACLE I showed that when erythromycin 
was given to women with PPROM, there was an associated increase in the 
number of women remaining undelivered after 7 days along with a range of 
health benefits for the neonate. Co-amoxiclav, however, was associated with an 
increased risk of necrotising enterocolitis in the neonate and therefore 
erythromycin has become the preferred choice for women with PPROM (225). 
The ORACLE II randomised control trial, however, found an increased risk of 
cerebral palsy at 7 years of age (OR 1.93; 95% CI 1.21-3.09 for erythromycin 
and OR 1.69; 95% CI 1.07-2.67 for co-amoxiclav) in children of women with 
intact membranes who received antibiotics for spontaneous preterm labour 
(226). This is likely to be because treating women with a sub-clinical infection 
could mask the infection and leave the fetus exposed to a hostile in utero 
environment, leaving the need for delivery going unnoticed. 
 
Until a better understanding of the causes of preterm birth exists, we will 
continue to fail in the pursuit to prevent or stop preterm birth. Preterm birth is a 
persisting problem with some effective interventions available. Unfortunately, 
due to the heterogeneous nature of the condition, it is still difficult to tailor the 
correct treatment for each woman. If we were able to better phenotype the 
individual, then we could direct the correct intervention to the correct patient. To 
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be able to do this we need to search for better predictive strategies to help 
identify these high-risk women. This will likely need novel strategies (-omic 
technology), multiple biomarker approaches or larger prospectively acquired 
databases.   
 
Using the SCOPE biobank, derived from a prospectively-acquired global cohort, 
this MD aimed to investigate three areas for their predictive ability: 
x clinical risk factors 
x biomarker discovery using proteomic technology 





2 Clinical Risk Factors for the Prediction of Spontaneous 
Preterm Birth 
2.1 Introduction 
The outcome of preterm birth arises from a number of different aetiologies, so it 
is probable that a variety of clinical factors (11-14) and biochemical changes 
(85, 86) may each confer increased risk, making accurate and consistent 
prediction and prevention difficult to achieve. 
 
Despite these challenges, elucidating reliable prediction strategies for preterm 
birth is an important target for several reasons. Firstly, accurate identification of 
at-risk women will allow initiation of risk-specific strategies such as the use of 
progesterone (140, 141, 203). Second, the risk factors themselves might define 
populations useful for further assessments and interventions such as cervical 
screening (72, 167) or cerclage (195). Finally, identification of risk factors might 
provide important insights into mechanisms leading to preterm birth.  
 
From a clinical point of view, women at risk of preterm birth are most commonly 
identified from their previous obstetric history, having had a preterm birth. As 
previously discussed, this excludes the primiparous population. More recently, 
there has been the appreciation that women with previous cervical surgery may 
also be at risk, so this group may be included, despite the lack of evidence to 
support subsequent monitoring. 
 
In addition to previous preterm birth, previously researched screening strategies 
have considered a range of other historical and demographic risk factors such 
as maternal age, race and smoking status. Several risk scoring systems have 
been developed. The most recognised risk assessment tool is the Creasy score 
(144), which was developed by ascribing a numerical value to individual risk 
factors and by weighting risk factors differently depending on their importance. It 
was devised by looking at all women (966 patients) who registered for delivery 
at the National Women’s Hospital in a 6 month period in 1978 in Auckland, New 
Zealand. They were screened at their initial booking visit and then again at 26-
28 weeks. The scoring system was based on socioeconomic status, past 
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obstetric history, daily habits and problems in their current pregnancy. Women 
were then placed in a low-, medium- or high-risk category. The incidence of 
preterm labour in the final groups was 2%, 5% and 30% in the low-, medium-, 
and high-risk groups respectively. Sixty four per cent of the preterm births came 
from the high-risk group. This predictive method, however, lacks sufficient 
sensitivity and specificity for routine clinical use. Many women who deliver 
preterm are not identified by the risk-scoring system and the majority of women 
identified as high risk will not deliver preterm. Furthermore, because a 
traditional risk factor score is based largely on previous obstetric history, as 
expected its accuracy is particularly poor among women expecting their first 
child, who comprise half of those affected by PTB.  
 
Another method of identifying high risk women is through the use of biomarkers, 
such as cervicovaginal fetal fibronectin (fFN). This is usually only used after 22 
weeks gestation and may only be positive just a few weeks prior to the preterm 
birth which may be too late for any preventive strategy. Cervical length 
measurement has also been shown to have potential in highlighting women in 
whom intervention, such as progesterone or cerclage, may be beneficial (142). 
 
The SCOPE (Screening for Pregnancy Endpoints) study, a prospective, 
multicentre cohort study of healthy nulliparous women had the primary aim of 
developing screening tests to predict pre-eclampsia, infants small for 
gestational age, and spontaneous preterm birth. A previous study (227), an 
analysis of the Southern hemisphere cohort, highlighted that different risk 
factors were present in women destined for spontaneous preterm birth following 
prelabour rupture of membranes or intact membranes. 
 
In this part of my thesis I set out to: 
x assess data from the global SCOPE cohort  
x define clinical risk factor algorithms associated with spontaneous preterm 
birth before and after 34 completed weeks 
x determine their predictive performance within a validation dataset 
x examine how additional scan-derived data (fetal anthropometry, uterine 




2.2 Methods  
Six centres (Auckland, New Zealand; Adelaide, Australia; London, Manchester 
and Leeds UK; and Cork, Ireland) recruited nulliparous women with singleton 
pregnancies to the SCOPE study between November 2004 and August 2008. 
Women (n=8351) attending hospital antenatal clinics, obstetricians, general 
practitioners, or community midwives before 15 weeks’ gestation were invited to 
participate. Exclusion criteria included women defined as high risk of pre- 
eclampsia, small for gestational age baby or spontaneous preterm birth 
because of underlying medical conditions (chronic hypertension requiring 
antihypertensive drugs, diabetes, renal disease, systemic lupus erythematosus, 
antiphospholipid syndrome, sickle cell disease, HIV), previous cervical knife 
cone biopsy, three or more terminations or three or more miscarriages, current 
ruptured membranes; known major fetal anomaly or abnormal karyotype; or 
intervention that could modify the outcome of pregnancy (such as aspirin, 
cervical suture).  
 
Research midwives interviewed and examined women at 14-16 and 19-21 
weeks’ gestation. Women underwent an ultrasound scan at 19-21 weeks. At the 
time of interview, data were entered on an internet-accessed central database 
with a complete audit trail (MedSciNet). At 14-16 weeks’ gestation the following 
data were collected: demographic information including age, ethnicity, 
immigration details, education, work, socioeconomic index, income level, living 
situation; the woman’s birth weight and gestation at delivery and whether it was 
a singleton or multiple pregnancy; previous miscarriages, terminations, or 
ectopic pregnancies and whether these pregnancies were with the same 
partner as the current pregnancy or not; history of infertility, use of assisted 
reproductive technologies, duration of sexual relationship, and exposure to 
partner’s sperm; gynaecological (including polycystic ovarian syndrome) and 
medical history, including hypertension while taking combined oral 
contraception, asthma, urinary tract infection, inflammatory bowel disease, 
thyroid disease, and thromboembolism; and family history (in mother and 
sisters) of obstetric complications (miscarriage, pre-eclampsia, eclampsia, 
gestational hypertension, spontaneous preterm birth, any preterm birth, 
gestational diabetes, stillbirth, and neonatal death) and family history (mother, 
father, sibling) of medical conditions (hypertension, coronary artery heart 
disease, cerebrovascular accident, type 1 and 2 diabetes, and venous 
thromboembolism). Information was collected on vaginal bleeding early in 
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pregnancy (gestation, severity and duration of bleeding, and recurrent bleeds), 
hyperemesis, and infections during pregnancy. Vegetarian status was recorded, 
and other dietary information before conception and during pregnancy was 
obtained from food frequency questions for fruit, green leafy vegetables, oily 
and other fish, and fast foods. Use of folate and multivitamins, cigarettes, 
alcohol (including binge drinking), and recreational drugs including marijuana, 
amphetamine, cocaine, heroin, ecstasy and LSD (lysergide) was recorded for 
before conception, first trimester, and at 15 weeks.  
 
A lifestyle questionnaire was completed assessing work, exercise and 
sedentary activities, snoring, domestic violence, and social support. 
Psychological scales were completed to measure perceived stress (228), 
depression (229), anxiety (230), and behavioural responses to pregnancy 
(adapted from the Behavioural Responses to Illness Questionnaire (231)). Two 
consecutive manual blood pressure measurements (mercury or aneroid 
sphygmomanometer, with a large cuff if the arm circumference ≥33 cm and 
Korotkoff V for diastolic blood pressure) were recorded. Other maternal 
measurements included maternal height and weight and waist, hip, arm, and 
head circumference. Proteinuria in a midstream urine specimen was measured 
by dipstick or by protein:creatinine ratio. Random whole blood glucose and 
serum lipid concentrations (triglycerides, total cholesterol, high density 
lipoprotein cholesterol, low density lipoprotein cholesterol, total cholesterol: high 
density lipoprotein cholesterol ratio) were also measured.  
 
Ultrasound examination at 19-21 weeks’ gestation included measurements of 
the fetus (biparietal diameter, head circumference, abdominal circumference, 
and femur length), and Doppler studies of the umbilical and uterine arteries 
(232). All fetal measurements were adjusted for gestational age by calculating 
the multiple of the median for each gestational week. Mean uterine resistance 
index (RI) was calculated from the left and right uterine resistance index. If only 
a left or right uterine resistance index was available, this was used as “mean 
resistance index” (n=20). The presence or absence of notching in each uterine 
artery was recorded. An abnormal uterine artery Doppler result was defined as 




Participants were followed prospectively, and research midwives collected data 
on pregnancy outcome and measurements of the baby. Data monitoring 
included individual checks of all data for each participant, including checks for 
any transcription errors of the lifestyle questionnaire, and detection of illogical or 
inconsistent data and outliers with customised software. 
 
2.2.1 Primary outcome 
The primary outcome was spontaneous preterm birth less than 37 weeks. Two 
subgroups were then formed: spontaneous preterm birth <34 completed weeks 
and spontaneous preterm birth 34-36 weeks. The referent group comprised 
women who delivered at ≥37 weeks.  
 
2.2.2 Other definitions 
The estimated date of delivery was calculated as follows: if the woman was 
certain of the date of her last menstrual period (LMP), the estimated date of 
delivery was adjusted only if a scan at <16 weeks’ gestation found a difference 
of seven or more days between the scan gestation and that calculated by the 
LMP or a scan at 20±1 weeks found a difference of 10 or more days. If her date 
was uncertain, scan dates were used to calculate the estimated date of delivery. 
 
2.2.3 Statistical analysis 
All analyses were performed using the statistical software R. Continuous clinical 
variables in cases and controls were compared using either ANOVA, Student’s 
t-test or the Wilcoxon Rank Sum, depending on data distribution. Categorical 
data were compared using either Chi-squared or the Fisher’s exact test. For 
creating and testing predictive models, training and validation datasets (ratio 
2:1) were created by randomly splitting the total dataset, stratified by 




2.2.4 Clinical variable selection 
Figure  2.1 demonstrates how the variables were selected for the algorithm. Of 
the original 1140 variables, 286 variables remained after the following 
exclusions: paternal variables (n=85), missing data >10% (variables added after 
recruitment commenced, work related variables, clinical labs n=149), not easily 
applied when screening future populations (n=70) or p>0.1 in univariate 
comparisons in the training dataset (n=550). Nineteen variables were selected 
from the remaining 286 variables using the following criteria for removal: no 
extreme outliers or small numbers (n<5) in subgroups (n=109), addressed by 
other variable (n=8), ease of collection in the clinical setting (n=26) and no 
biological plausibility as risk factors for preterm birth (n=124). 
 
Of the final 19 variables used for model building, 12 had no missing data, 3 had 
<1% missing data, 3 had between 1 and 5% missing data and 1 (cervical length 
scan) had 46% missing data. Missing clinical data was imputed with expectation 
maximisation (233) and used the median for three variables unrelated to the 
observed data. The expectation maximisation algorithm was implemented in the 
“mix” package in R, version 2.9.1 (234). For fetal biometry and uterine artery 
Doppler data, individuals with missing data were deleted. 
 
Backwards logistic regression models were constructed for each endpoint in the 
training dataset. The model construction for each endpoint was performed with 
three sets of variables:  
(1) clinical risk factors obtained at 14-16 weeks’ gestation  
(2) clinical risk factors plus ultrasound scan measurements of fetal growth 
and uterine artery resistance index at 19-21 weeks  
(3) clinical risk factors plus ultrasound scan measurements of fetal growth, 
uterine artery resistance index and cervical length at 19-21 weeks.  









   
1140 variables 
Stage 1 deletion 
•Paternal variables (n=85) 
Stage 2 deletion 
•Not easily applied to future population (n=70) 
•Missing data >10% (n=149) 
Stage 3 deletion 
•p>0.1 on univariate analysis (n=550) 
Stage 4 deletion 
•Low cell count <5 (n=109) 
•Addressed by other variable (n=8) 
•Lack of ease in collection in clinical setting (n=26) 
Stage 5 deletion 
•No biological plausability as risk factor for 
preterm birth (n=124) 




2.3.1 Recruitment and characteristics of participants 
Seventy one percent (n=5989) of the 8351 women approached initially agreed 
to participate (Figure  2.2). Of the 5690 women recruited, pregnancy outcome 
was available in 5628 (99%). Two hundred and thirty six women (4.2%) had a 
spontaneous preterm birth, of whom 71 (30%) were delivered before 34 weeks 
and 165 (70%) delivered between 34 and 36 weeks. Among PTB cases 
delivered before 34 weeks, 34 (48%) had preterm prelabour rupture of 
membranes (PTB-PPROM) and 37 (52%) had intact membranes at the time of 
labour (PTB-IM). Similarly, PTB cases who delivered between 34-36 weeks 
comprised 72 (44%) PTB-PPROM and 93 (56%) PTB-IM. The median gestation 
at delivery was similar for PTB-PPROM [35.0 (interquartile range 33.2-36.3) 
weeks, n=106] and PTB-IM [35.6 (IQR 33.7-36.4) weeks, n=130, p=0.23]. 
 
Of the 851 women with an elevated mean uterine artery or bilateral notches, 
only 43 (5.1%) resulted in spontaneous PTB cases, 18.2% of the total number 
of spontaneous PTB cases (236). Of the 3009 women with cervical length 
measured, only 48 (1.6%) and 6 (0.2%), had a transvaginal cervical length less 
than 25 mm and less than 15 mm, respectively. Of the 48 with a cervix <25 mm, 
only two had spontaneous PTB. 
 
After randomly splitting the dataset, there were 3752 women in the training and 
1876 women in the validation datasets (Figure  2.2). After exclusion of 
participants who had a miscarriage or termination before 22 weeks or for whom 
there were missing fetal or uterine artery Doppler scan parameters, 96% of 
participants remained in the training (n=3583) and validation (n=1796) datasets. 
Transvaginal cervical length assessment was an optional component of 
consent, and these data were available in 56% of the women in both the 
training and validation datasets. The distribution of centres and preterm birth 
phenotypes in the training and validation datasets were very similar (Table  2-1). 
 
Maternal characteristics and pregnancy outcomes in control pregnancies, and 
those spontaneous preterm births delivered before 34 weeks and at 34-36 









Table ‎2-1 Distribution of centres and preterm birth phenotypes in the 


























Spontaneous PTB 160 (4) 76 (4) 
sPTB <34 weeks 48 (1) 23 (1) 





Table ‎2-2. Maternal Characteristics and Pregnancy Outcome  










Maternal characteristics and 
outcome 
    
Maternal age (y) 28.6 (6) 28.1 (6) 28.7 (6) 0.41 
Caucasian  61 (86) 152 (92) 4848 (90) 0.34 
Married/defacto 57 (80) 155 (94) 4876 (90) 0.005 
Socioeconomic Index 37.5 (15) 41.7 (17) 41.9 (16) 0.07 
Education <12 years schooling 34 (48) 82 (50) 2008 (37) 0.001 
Tertiary education  50 (70) 124 (75) 4498 (83) 0.0004 
Full/part time work 53 (75) 140 (85) 4606 (85) 0.04 
Unemployed/beneficiary 14 (20) 19 (12) 427 (8) 0.0004 
Primigravida  46 (65) 114 (69) 4171 (77) 0.002 



















non smoker  
















Family history PTB 
single preterm birth 


























































Systolic blood pressure (mmHg) at 
15w 108 (11) 107 (11) 107 (11) 0.44 
Diastolic blood pressure (mmHg)at 
15w 67 (8) 65 (8) 65 (8) 0.31 
Preeclampsia 2 (3) 5 (3) 271 (5) 0.69 
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Placental Abruption 9 (13) 3 (2) 31 (1) < 0.0001 
Fetal Outcome     
Delivery gestation (weeks) 29.2 (4.4) 35.8 (0.9) 39.8 (2.1) < 0.0001 
Birth weight (g) 1451 (704) 2711 (426) 3436 (572) < 0.0001 
SGA (<10th customised centile) 10 (14) 16 (10) 607 (11) < 0.0001 
Customised Birth weight centile 40 (32) 53 (31) 47 (29) 0.75 
Admission to neonatal unit 57 (80) 100 (61) 490 (9) < 0.0001 
Perinatal death 10 (14.1) 1 (0.6) 20 (0.4) < 0.0001 
Values are “mean (sd)” for continuous variables, and “number (percentage)” for 
discrete variables. P-values generated by one-way ANOVA for continuous 






2.3.2 Variables of the algorithm at 15 weeks gestation 
Of the 19 variables used for the model building, some were better performing 
than others for each sub-phenotype. The clinical risk factors recorded at 15 
weeks’ gestation that performed best for each of the phenotypes following 
multivariate analysis are included in the models. They are shown along with 
their odds ratios for the different sub-phenotypes in Table  2-3, Table  2-4 and 
Table  2-5. The cervical length scan variable is not included in these models as 
this made no difference to the performance of the algorithm (see Table  2-9). 
 
Table ‎2-3 Clinical risk factors at 15 weeks gestation for spontaneous 
preterm birth less than 34 weeks 
Clinical Risk Factor Odds ratio 
One vaginal bleed before 15w 1.94 (0.91,3.86) 
≥ 2 vaginal bleeds before 15w 5.11 (2.21,10.82) 
>12 months to conceive with current partner 2.07 (0.99,4) 
One previous miscarriage 1.32 (0.53,2.82) 
≥2 miscarriages 3.62 (1.01,9.94) 
Consumed/inhaled/injected other recreational drugs at 
gestation at 15w 4.7 (1.43,12.8) 
Unemployed or sickness beneficiary at 15 w 2.08 (0.85,4.6) 
Any folate intake in 1st trimester 0.44 (0.17,1.3) 





Table ‎2-4 Clinical risk factors at 15 weeks gestation for spontaneous 
preterm birth at 34-36 weeks gestation 
Clinical Risk Factor Odds ratio  
One vaginal bleed before 15w 1.86 (1.18,2.86) 
≥ 2 vaginal bleeds before 15w 1.13 (0.43,2.42) 
Participant’s birthweight 1.19 (1.01,1.39) 
Family history of pre-eclampsia (first degree relative) 1.81 (1.04,2.99) 
Any sister had a history of LBW baby 2.6 (1.22,5.01) 
Quit smoking in pregnancy 0.55 (0.24,1.08) 
Smoking at 15w pregnancy 1.85 (1.11,2.95) 
 
 
Table ‎2-5 Clinical risk factors at 15 weeks gestation for all spontaneous 
preterm birth 
Clinical Risk Factor Odds ratio 
One vaginal bleed before 15w 1.94 (1.31,2.81) 
≥ 2 vaginal bleeds before 15w 2.13 (1.16,3.66) 
>12 months to conceive with current partner 1.66 (1.08,2.49) 
Participant’s birthweight 1.14 (0.99,1.31) 
Family history of pre-eclampsia (first degree relative) 1.57 (0.96,2.45) 
One previous miscarriage 1.04 (0.62,1.65) 
≥2 miscarriages 2.82 (1.26,5.63) 
Any sister had a history of LBW baby 1.85 (0.9,3.46) 
Quit smoking in pregnancy 0.7 (0.39,1.18) 
Smoking at 15w pregnancy 1.45 (0.89,2.28) 
Consumed/inhaled/injected other recreational drugs at 
gestation at 15w 2.61 (1.11,5.59) 




2.3.3 Variables of the algorithm at 20 weeks gestation 
The odds ratios of the included clinical risk factors from 15 weeks gestation and 
the Dopplers and fetal biometry at 20 weeks are shown in Table  2-6, Table  2-7 
and Table  2-8. 
 
In comparison to the 15 weeks models, for sPTB less than 34 weeks, history of 
previous miscarriages, folate and oily fish intake were no longer included in the 
algorithm whereas alcohol intake was now included. Uterine artery Doppler and 
fetal biometry were not identified as being important in this algorithm. The sPTB 
34-36 weeks algorithm required the uterine artery Doppler and fetal biometry 
variables to be included along with level of education. The all sPTB algorithm 
required the addition of uterine artery Doppler and fetal biometry variables but 
no longer included previous history of miscarriage. Cervical length data again 
did not improve the prediction and is therefore not included (see Table  2-9).  
 
Table ‎2-6 Clinical risk factors and scan data at 20 weeks for the prediction 
of spontaneous preterm birth less than 34 weeks 
Clinical Risk + Doppler + Biometry Odds ratio 
One vaginal bleed before 15w 1.97 (0.89,4.05) 
≥ 2 vaginal bleeds before 15w 3.94 (1.43,9.31) 
>12 months to conceive with current partner 2.22 (1.02,4.48) 
Consumed/inhaled/injected other recreational drugs at 
gestation at 15w 6.88 (2.12,18.72) 
Units of alcohol per week in 1st trimester 0.61 (0.32,1.15) 






Table ‎2-7 Clinical risk factors and scan data at 20 weeks for the prediction 
of spontaneous preterm birth at 34-36 weeks gestation 
Clinical Risk + Doppler + Biometry Odds ratio 
One vaginal bleed before 15w 1.8 (1.12,2.81) 
≥ 2 vaginal bleeds before 15w 1.22 (0.47,2.64) 
Participant’s birthweight 1.18 (1,1.39) 
Family history of pre-eclampsia (first degree relative) 1.8 (1.03,2.99) 
Any sister had a history of LBW baby 2.57 (1.2,5) 
Quit smoking in pregnancy 0.49 (0.2,1) 
Smoking at 15w pregnancy 1.71 (1,2.8) 
Mean uterine artery RI at 19-21w 0.83 (0.69,1) 
Head circumference: abdominal circumference ratio at 
19-21w 0.64 (0.45,0.91) 






Table ‎2-8 Clinical risk factors and scan data at 20 for the prediction of all 
spontaneous preterm birth 
Clinical Risk + Doppler + Biometry Odds ratio 
One vaginal bleed before 15w 1.9 (1.27,2.8) 
≥ 2 vaginal bleeds before 15w 1.92 (0.98,3.45) 
>12 months to conceive with current partner 1.61 (1.02,2.46) 
Participant’s birthweight 1.16 (1.01,1.34) 
Family history of pre-eclampsia (first degree relative) 1.62 (0.98,2.56) 
Any sister had a history of LBW baby 1.98 (0.96,3.73) 
Quit smoking in pregnancy 0.6 (0.31,1.06) 
Smoking at 15w pregnancy 1.52 (0.93,2.4) 
Consumed/inhaled/injected other recreational drugs at 
gestation at 15w 2.72 (1.14,5.9) 
Mean uterine artery RI at 19-21w 0.85 (0.72,1) 
Head circumference: abdominal circumference ratio at 
19-21w 0.68 (0.5,0.92) 




2.3.4 Performance of the clinical risk factor algorithms  
The model performances in the training and validation datasets for the different 
endpoints, using the three different sets of variables, are shown in Table  2-9. 
The addition of fetal biometry, Doppler and cervical length data did not improve 
the performance of any of the models.  
 
The model which performed the best was the one to predict preterm birth <34 
weeks gestation with an AUC of 0.74, which achieved a similar performance 
(AUC 0.75) in the validation dataset. 
 
Table ‎2-9 Model performance in training and validation sets for different 
end points 
 AUC (95% CI) in 
training dataset 
AUC (95% CI) in validation 
dataset 
PTB <34 weeks     
Clinical 0.74 (0.67,0.81) 0.75 (0.65,0.85) 
Clinical + Doppler + Biometry 0.72 (0.64,0.80) 0.69 (0.56,0.82) 
Clinical + Doppler + Biometry + 
Cervical length 0.65 (0.53,0.77) 0.55 (0.41,0.68) 
PTB 34-36 weeks     
Clinical 0.65 (0.60,0.70) 0.50 (0.42,0.58) 
Clinical + Doppler 0.69 (0.64,0.74) 0.51 (0.43,0.60) 
Clinical + Doppler + Biometry + 
Cervical length 0.70 (0.64,0.76) 0.53 (0.40,0.65) 
PTB all    
Clinical 0.66 (0.62,0.70) 0.60 (0.53,0.67) 
Clinical + Doppler + Biometry 0.68 (0.64,0.73) 0.57 (0.49,0.64) 
Clinical + Doppler + Biometry + 





2.3.5 Clinical risk factor algorithm for spontaneous preterm birth 
<34 weeks using multivariate analysis 
The spontaneous preterm birth less than 34 weeks gestation clinical risk factor 
algorithm performed the best and was equally as good when tested in the 
validation dataset. Table  2-10 shows the clinical risk factors identified as being 
most important for identifying nulliparous women at risk of preterm birth less 
than 34 weeks and the frequencies in each group of the SCOPE cohort. 
Table ‎2-10 Clinical risk factors at 15 weeks included in clinical risk factor 
algorithm for preterm birth <34 weeks 
 Clinical risk factors at 15 weeks 









One vaginal bleed before 15w  
870 (16) 20 (28) 
1.94 
(0.91,3.86) 
≥ 2 vaginal bleeds before 15w 
305 (5) 12 (17) 
5.11 
(2.21,10.82) 
>12 months to conceive with current partner  680 (12) 18 (25) 2.07 (0.99,4) 
Consumed/inhaled/injected other recreational 
drugs at gestation at 15w  77 (1) 7 (10) 4.7 (1.43,12.8) 
Unemployed or sickness beneficiary at 15 w 446 (8) 14 (20) 2.08 (0.85,4.6) 
One previous miscarriage 




103 (2) 8 (11) 
3.62 
(1.01,9.94) 
Any folate intake in 1st trimester 5340 (96) 61 (86) 0.44 (0.17,1.3) 
Did not consume oily fish in pregnancy prior to 
15w  2221 (40) 34 (48) 
1.57 
(0.87,2.82) 
Model formulae for PTB <34 weeks: 
15 week model: -4.48 + 0.73*unemployed or sickness beneficiary at 15 weeks+0.27*one previous 
miscarriage+1.29*two or more miscarriages+0.73*more than 12 months to conceive with current 
partner+0.66*one vaginal bleed before 15w+1.63*two or more vaginal bleeds before 15w+0.45*did not 
consume oily fish in pregnancy prior to 15w-0.82*any folate intake in 1st trimester. 
.   
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2.3.6 Prediction of spontaneous preterm birth <34 weeks in the 
training and validation sets 
The algorithm was used to predict spontaneous preterm birth <34 weeks in both 
the training and validation sets for comparison.  
Table  2-11 shows the performance of the algorithm for the prediction of 
spontaneous preterm birth <34 weeks based on clinical risk factors at 15 weeks’ 
gestation in training and validation sets. 
. 
Table ‎2-11 Prediction of spontaneous preterm birth <34 weeks based on 
clinical risk factors at 15 weeks gestation in training and validation sets 
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Traditional methods of screening for preterm birth have been based on obstetric 
history, current symptoms or epidemiological risk factors such as maternal age, 
race and smoking status. The most commonly known scoring system is 
Creasy’s score (144), which is a modified Papiernik-Berkhauer system (235). 
However, these methods fail to identify over 50% of pregnancies that deliver 
preterm (i.e. they have a low sensitivity) and the majority of women who screen 
positive will ultimately deliver at term (i.e. they also have low positive predictive 
values).  
 
The single greatest risk factor for preterm birth is a history of a prior 
unexplained spontaneous preterm birth, with a history of two prior preterm births 
yielding a risk of over 50% (90, 236). The model yielded through this large 
prospective international cohort of healthy nulliparous women by necessity does 
not include this risk factor, which therefore potentially makes it useful for other 
nulliparous women, who contribute around half of all preterm births (237). Using 
information which can be acquired in early pregnancy a clinical risk factor 
algorithm with a modest predictive performance for spontaneous preterm birth 
in both discovery and validation datasets has been developed. This study has 
highlighted other less well known risks which appear important, such as vaginal 
bleeding in early pregnancy, prior early miscarriage, months to conceive with 
current partner, unemployment, use of recreational drugs, folate intake and lack 
of consumption of oily fish. 
 
The algorithm and collection of risk factors for the most clinically relevant group 
of preterm birth, those delivering less than 34 weeks, exhibited the best 
predictive performance overall – the area under the receiver operating 
characteristics curve was 0.74 – with an excellent negative predictive value of 
99%. However, only 33% of preterm births in this group would have been 
predicted using the algorithm. The performance was similar (with a sensitivity of 
35% and NPV of 99%) when we tested the algorithm on the validation cohort. 
The addition of ultrasonographic details, (biometry, Doppler and cervical length) 
did not improve performance, in part due to the very small numbers of women 
who had a preterm birth when this was measured. This identified risk 
assessment tool was more significant for the clinically important early (<34 
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weeks) preterm cohort as opposed to the later group (34-36 weeks). Although 
this may identify smaller numbers of preterm babies, they account for the 
greatest proportion of perinatal morbidity and mortality and long-term disability. 
There are clear patterns in the risk factors highlighted in this algorithm which 
demonstrates the multifactorial nature of preterm birth (18, 23). 
 
Socioeconomic status 
Low socio-economic status (SES) has previously been strongly linked to 
prematurity (96, 103, 105, 128-130, 238-242) and the algorithm has identified 
unemployment or sickness beneficiary and drug use as being important risk 
factors for spontaneous preterm birth. All these factors are more prominent in 
the most deprived areas. Socio-economic disadvantage is unlikely to be a 
direct, independent determinant of preterm birth; instead, it probably leads to 
less healthy behaviour, exposure to psychosocial stress and social evaluative 
threat, and psychological reactions to stress that shorten gestation (105). The 
contributions of genital tract colonisation, infection and inflammation have been 
identified as significant predictors of preterm birth, particularly for early preterm 
birth (<32 weeks) and bacterial vaginosis is more common among the socially 
disadvantaged (26, 34, 106-110). Several case-control studies have 
demonstrated an increased risk of spontaneous preterm birth in women who are 
unemployed (OR 1.5)(243). This can be found to be even higher in women 
receiving unemployment or sickness benefit (very preterm birth OR 1.88-2.64) 
(244, 245). 
 
It has been shown that pregnant women living in low SES areas experience 
more stressful life events during their pregnancy and chronic stressors often 
result from the environment they live in (101, 111-113). These include financial 
insecurities, poor and crowded housing conditions, living without a partner, 
unsatisfying marital relationships, domestic violence, and stressful working 
conditions (101, 114, 115). They also often have a more restricted social 
support network (116) which is often less available during their pregnancy which 
can increase the impact of those stressors. 
 
Toxins 
Recreational drug use was another important risk factor. Cocaine use, although 
generally low during pregnancy, has previously been associated with preterm 
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birth (105, 246-248). However, in poor, inner-city areas, its use during 
pregnancy may be extremely prevalent (249), and in these settings, its 
mediating role may be substantial. Marijuana (250, 251) and narcotic (252) use, 
and high alcohol (253-255) and caffeine (>300mg/day) (256, 257) consumption 
are also more common among the socially disadvantaged, but these factors 
have not been convincingly shown to have an impact on gestational duration 
(242, 246-248, 257-263). 
 
Nutrition  
The nutritional status of the mother has previously demonstrated a clear 
association with preterm birth (264). The algorithm highlighted the lack of oily 
fish consumption (265-267) and use of folate in the first trimester as being 
important, which was in keeping with previous studies. Fish oil supplementation 
has been shown to prolong gestation in pregnant women with the most marked 
differences in those with previous pregnancy complications and in low and 
middle, but not in high, fish consumers (267-269). Recent reports suggest that 
low folic acid intake increases the risk of preterm delivery and that 
supplementation may be associated with a 50-70% reduction in early 
spontaneous preterm birth (270-272). 
 
Fertility history 
Taking more than 12 months to conceive with one’s current partner was another 
variable identified in this analysis and this has previously been demonstrated in 
a study in Denmark (273). Women who have suffered a threatened miscarriage 
have been independently shown to have an increased incidence of preterm 
delivery (50, 274).  
 
Implantation/placentation 
Vaginal bleeding and number of miscarriages may be reflective of disruption at 
the uteroplacental interface (275). Bleeding in early pregnancy most often 
originates from the placenta and it is thought that bleeding between the 
chorionic membrane and the uterine wall may result in a spectrum of effects on 
pregnancy development and outcome. At the end of pregnancy this is likely to 
be due to a chronic inflammatory reaction within the decidua and placental 
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membranes, with weakening and eventual rupture of the membranes or 
resulting in myometrial activity (275-281). 
 
The derived algorithms are likely to be indicative of the best performance 
achievable using clinical and ultrasonographic data to predict preterm birth in a 
healthy nulliparous population, because of the study’s prospective design, 
cohort size, comprehensive range of candidate predictors, high quality data, 
and completeness to follow-up. Clinical risk estimates for disease are already 
established in other areas of medicine and biomarkers are often added to 
improve performance. Unfortunately there have been no clinically useful 
biomarkers identified for spontaneous preterm birth yet (282), although these 
remain the subject of intense interest. 
 
The cohort size was sufficient to permit division into a training and validation 
cohort. Other strengths of the study included prospective acquisition of high 
quality data from questionnaires administered at face to face interviews, 
informed by detailed standard operating procedures and the use of a real-time 
database, with automatic checking procedures, ensuring reduced data entry 
and transcription errors. For a dataset of this size, the rate of missing data was 
extremely low. The intensive two-stage data monitoring added confidence in 
data integrity. 
 
Despite these strengths, there will always be limitations in such far-ranging data 
collection. It is likely that measurement errors, such as in self-reported family 
history (283) could have occurred. The outcome data for each case were 
reviewed by the local principal investigators which ensured accurate and 
consistent diagnosis of spontaneous preterm birth. One of the challenges when 
predicting rare events in prospective cohorts such as SCOPE is the relatively 
low number of cases compared with those studies derived from larger but less 
detailed epidemiological databases. While the latter might have substantially 
greater number of events, their interpretation is constrained by less accurate 
diagnosis. 
 
There is no consensus as to the best method for selection of clinical variables 
(284). Given the rich dataset of potential predictors for preterm birth, an initial 
reduction step based on significance of univariate testing was used and then 
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selection of a subset of candidate variables based on a priori knowledge. 
Although this could have introduced variable selection bias, it was reassuring 
that the clinical risk factors and their strength of association with preterm birth 
were consistent with the literature. 
 
The ideal use of a predictive tool would be to identify healthy nulliparous women 
at low or high risk for spontaneous preterm birth. Those at low risk could 
continue with standard antenatal care, whereas high risk women would follow a 
more intensive pathway, such as ultrasound assessment of cervical length, or 
fetal fibronectin testing, to allow early initiation of targeted interventions, such as 
supplemental progesterone or cerclage.  
 
The large multicentre prospective design with excellent follow-up is a major 
strength of this study. The ultimate aim of the SCOPE study is to develop tests 
to predict pregnancy outcome with potential to translate into clinical care. The 
population in which the algorithm is developed needs to be identifiable if a 
screening test is to be used in clinical care (285) and recruitment has been a 
clearly defined population of nulliparous women to enable the detection of 
similar populations for validation and clinical use. Important clinical risk factors 
in healthy nulliparous women for spontaneous preterm birth at less than 34 
weeks gestation have been identified. The algorithm provides a modest 
improvement in predictive performance compared with current practice. It has 
been validated in a separate sample set, however will need further validation in 
a separate cohort.  
 
Disease biomarkers may improve the prediction further but as yet no useful 
biomarkers have been identified to improve the prediction of spontaneous 
preterm birth. It may be that a clinical risk factor-biomarker combination is likely 
to yield the best clinical performance, such as that used in Down’s syndrome 
screening (286-288).The next part of my thesis will be to investigate the plasma 




3 Proteomic Identification of Biomarkers for the Prediction of 
Spontaneous Preterm Birth  
3.1 Introduction  
Proteomics can be defined as the systematic analysis of proteins for their 
identity, quantity and function, in a non-targeted and unbiased manner. The 
proteome is dynamic, varying in response to external and internal influences 
during development, ageing, health and disease (289). 
 
The proteome is the total set of expressed proteins in a cell, tissue or organism 
(290). There are estimated to be over 100,000 proteins compared to just 30,000 
genes (290). As the function of proteins is so closely tied to their cellular, tissue 
and physiological context, the ultimate goal is to characterise the information 
flow through protein pathways and networks (291), with an eventual aim to 
understand the functional relevance of proteins under disease conditions (292). 
Proteomic methods are hypothesis generating and allow the simultaneous 
analysis of many molecules including known and novel candidates, and are 
therefore ideally placed to search for biomarkers (290). As a result of the 
heterogeneous nature of humans and the complexity of disease, especially 
preterm birth, a panel of biomarkers rather than a single marker may be 
required to achieve the high sensitivity and specificity required for clinical 
applications (293). 
 
Proteomics is a particularly rich source of biological information because 
proteins are involved in almost all biological activities and changes in protein 
structure and expression levels signal, in most cases, the presence of disease 
(291). This means that proteins may be excellent targets in disease diagnostics, 
prognostics and therapeutics. 
 
Human plasma is an extreme challenge to study due to the large dynamic range 
of the proteins of interest. The proteins in human plasma range from common 
“high-abundance” proteins, comprising 2%-50% of the total protein mass 
(typically the µg/mL-mg/mL range) to those considered to be the more specific 




high abundance proteins account for 99% of the plasma proteome by mass, the 
transport protein albumin for 50% alone (295). The remaining 1% are low 
abundance proteins: cytokines, chemokines and peptide hormones, which are 
of primary interest for biomarker discovery (295). Removal of the most 
abundant components by immunodepletion or fractionation before analysis has 
markedly expanded the number of lower abundance components that can be 
detected (294). 
 
Once samples have been depleted of the most abundant proteins, fractionation 
is required to simplify the samples further. This allows the plasma samples to be 
separated out into fractions containing different low abundance proteins. 
 
3.1.1 Immunodepletion 
The presence of higher abundance proteins interferes with the identification and 
quantification of lower abundance proteins. While biomarkers could be found at 
any abundance level, the chances of finding a biomarker will increase with the 
number of proteins profiled (296). In addition, the more promising biomarkers 
are more likely to be the low abundant proteins that either leak into the plasma 
from different tissues as a result of disease or play a role as signal molecules, 
rather than the more common generic plasma proteins (297). 
 
Albumin, in very high abundance, is an ideal candidate for complete selective 
removal prior to performing a proteomic analysis of lower abundance proteins. 
However, depletion also results in a risk of losing proteins of interest other than 
those specifically depleted. It is well known that albumin interacts with a diverse 
number of compounds, such as low abundance cytokines, peptide hormones 
and lipoproteins, compounds that might be of interest in biomarker discovery. 
Therefore, depletion of the transport and carrier protein albumin under non-
denaturing conditions may lead to the depletion of many other potentially 
interesting compounds. However, no single proteomic technique is capable of 
visualizing every component of a proteome and compromises are always 
required. Instead each technique displays a different analytical window of 
proteins and depletion strategies should simply be seen as one way of 
extending the analytical window so that more potentially interesting proteins 





Depletion has become a routine and accepted technique and a number of 
methods are available. Traditionally this issue is tackled using immunodepletion 
columns to specifically remove the most abundant proteins. These columns are 
expensive and have limited loading capacity. It involves the application of 
plasma to immobilised purified polyclonal antibodies in order to remove these 
proteins (298). 
 
3.1.1.1 Multiple Affinity Removal Column (MARS) 
Various commercial products are available for depletion. When compared to 
other methods the Agilent Multiple Affinity Removal Column (MARS, Agilent 
Technologies Inc, CA) offers good depletion efficiency, specificity and 
reproducibility (296). A MARS column has been developed which can deplete 
14 high-abundant proteins, removing approximately 94% of the total protein 
mass. The 14 high-abundant proteins are human serum albumin, transferrin, 
haptoglobin, IgG, IgA, α1-antitrypsin, fibrinogen, α2-macroglobulin, α1-acid 
glycoprotein, complement C3, IgM, apolipoprotein AI, apolipoprotein AII and 
transthyretin. MARS columns are highly reproducible from sample to sample 
without introducing additional variation (296). Reproducibility is a prerequisite 
for accurate quantitative protein profiling for biomarker discovery. 
 
3.1.1.2 ProteoMinerTM Beads 
ProteoMinerTM technology (Bio-Rad Laboratories Inc, CA) is a novel sample 
preparation tool used for the compression of the dynamic range of the protein 
concentration in complex biological samples. This is accomplished through the 
use of a large, highly diverse bead-based library of combinatorial peptide 
ligands. Each bead features a different hexapeptide ligand with affinity for 
specific proteins in a sample. Samples are applied to the beads, allowing 
proteins to bind ligands to which they have the highest affinity. Proteins in 
excess are washed away, and those proteins bound to the beads are eventually 
eluted, allowing further downstream analysis. In contrast, the medium- and low-
abundance proteins are concentrated on their specific affinity ligands. This 
reduces the dynamic range of protein concentrations whilst maintaining 





3.1.2 High Performance Liquid Chromatography 
Once the samples are depleted of the most abundant proteins, the next step is 
to simplify the sample further using fractionation. This is commonly applied in 
multiple dimensions by high performance liquid chromatography (HPLC) 
producing a simplified fraction separated by different properties (299). 
 
The Agilent mRP-C18 column provides optimised separation by hydrophobicity 
for human serum after depletion of the high-abundance proteins using the 
MARS column. This combined workflow enables high recovery, excellent 
resolution and reproducibility in reducing sample complexity for biomarker 
research. The ability to recover >98% of immunodepleted plasma also provides 
the opportunity to validate biomarkers that are differentially expressed in control 
versus disease/treated plasma. The ability to reproducibly fractionate at the 
protein level with high resolution enables efficient separation and reduced 
overlap of proteins in collected RPLC fractions. 
 
3.1.3 Identification of proteins using Mass Spectrometry 
Once samples have been depleted and fractionated they can be analysed by a 
mass spectrometer (MS). The MS has low sensitivity for intact proteins and so 
samples are usually cleaved into peptides by a protease (usually trypsin) to 
allow identification and analysis. Mass spectrometry is capable of producing, 
separating and detecting molecular ions (297). 
 
3.1.4 Quantification methods in Mass Spectrometry 
Many potential diagnostic applications of proteomics depend on quantification of 
proteins in addition to their identification. The size of the peaks generated within 
the mass spectrum, indicate the intensity, i.e. the number of ions detected, at 
each m/z; however this information can only be used for relative quantification 
as it does not correlate with the amount of protein in the original sample. 
Quantitative MS methods can be divided into those using stable isotope labels, 
and those which are ‘label free’. Stable isotope labelling methods involve 
chemical modification of peptides to incorporate stable isotopes, labelled 
peptides behave almost identically to non labelled peptides but the differences 
in mass can be detected by the MS. Label free quantification can be achieved 




3.1.4.1 Isobaric Tags for Relative and Absolute Quantification (iTRAQ) 
This strategy is a ‘shotgun’ proteomics approach using iTRAQ labelling to 
achieve relative quantification (301-304). The iTRAQ kit allows the differential 
labelling of peptides from distinct proteomes. The labels consist of three 
elements, a peptide reactive group that enables the N-terminal labelling of 
peptides, a balance group that ensures labels are indistinguishable by mass, 
and a reporter group of variable mass which enables them to be differentiated 
by the release of this reporter ion. The iTRAQ kit can be used to label up to 
eight samples which can then be treated as one in subsequent fractionation 
steps, allowing for deep plasma penetration at the expense of high sample 
throughput. During tandem-MS, the peptide fragments into a product ion series 
which is used for peptide sequencing by database searching, and an iTRAQ 
reporter ion which is used for relative quantification (305). All individual plasma 
samples are referenced against the same ‘master pool’ allowing inter-
experiment comparisons to be made. 
 
Most labelling based quantification methods have limitations; which include 
increased time and complexity of sample preparation, requirement for higher 
sample concentration, high cost of the reagents, incomplete labelling, and the 
requirement for specific quantification software. Moreover, iTRAQ experiments 
are limited to the comparison of eight samples in a single experiment and are 
therefore often used for pooled samples.  
 
3.1.4.2 Label Free Method 
All label-free techniques include the following fundamental steps: (i) sample 
preparation including protein extraction, reduction, alkylation, and digestion; (ii) 
sample separation by liquid chromatography (LC or LC/LC) and analysis by 
MS/MS; (iii) data analysis including peptide/protein identification, quantification, 
and statistical analysis. This allows high sample throughput at the expense of 
reduced proteome penetration. In contrast to peptide-labelling methods, label 
free quantification allows you to analyse a larger number of individual samples 
rather than analysing pooled samples. 
 
Peptide quantification is generally based on two categories of measurements. 
The first is the measurements of ion intensity changes such as peptide peak 




identified peptides after MS/MS analysis. Peptide peak intensity or spectral 
count is measured for individual LC-MS/MS runs and changes in peptide 
abundance are calculated via a direct comparison between different analyses. 
Compared with isotope labelling methods, label-free quantification needs to be 
more carefully controlled, due to the possible error which may be introduced by 
run-to- run variations in the performance of the LC and MS(306).   
 
3.1.5 MS Limitations 
The application of mass spectrometry methods to proteomic biomarker 
identification is ideal due to the ability to analyse complex mixtures without prior 
knowledge of the components. The greatest limitations of mass spectrometry 
analyses are the sensitivity of the instruments and their ability to handle 
complex mixtures, although this technique continues to show promise in the 
search for biomarkers (307).  
 
3.2 Aim of this study 
Spontaneous preterm birth is well suited to a proteomic approach given the 
likely serologic changes that precede its clinical manifestation. The hypothesis 
is that proteomic differences exist in maternal plasma several weeks prior to the 
onset of clinical symptoms in women destined to develop spontaneous preterm 
birth. The aim is to use plasma proteomics to differentiate women having a 






3.3.1 Patient Plasma Samples  
EDTA-plasma from women at 20±1 weeks gestation who had uncomplicated 
pregnancies (controls) or who subsequently delivered prematurely were 
obtained from the SCOPE biobank (Auckland, New Zealand). Blood was 
collected by venepuncture into BD EDTA-Vacutainers®, placed on ice and 
centrifuged at 2400 x g for 10 minutes at 4°C. Plasma was stored at -80°C 
within four hours of collection. Sample collection and storage conditions were 
closely regulated for all samples. Plasma samples were defrosted on ice and 
always maintained below 4ºC during experiments.   
 
3.3.1.1 Ethical Approval and Participants  
The participants were healthy nulliparous women with singleton pregnancies 
recruited to the Screening for Pregnancy Endpoints (SCOPE) study between 
November 2004 to July 2007 in Auckland, New Zealand and Adelaide, Australia 
(Australian and New Zealand Clinical Trials Registry ACTRN12607000551493) 
(308). SCOPE was a prospective, multicentre cohort study with the main aim of 
developing screening tests to predict pre-eclampsia, small for gestational age 
infants, and spontaneous preterm birth. 
 
The women were recruited to the SCOPE study (see  2.2) between 14 and 16 
weeks through hospital antenatal clinics, obstetricians, general practitioners, 
community midwives, and self-referral in response to advertisements or 
recommendations of friends. Women were excluded if they were judged to be at 
high risk of pre-eclampsia, small for gestational age babies, or spontaneous 
preterm birth because of underlying medical conditions (chronic hypertension 
requiring antihypertensive drugs, diabetes, renal disease, systemic lupus 
erythematosus, antiphospholipid syndrome, sickle cell disease, HIV), previous 
cervical cone biopsy, three or more previous miscarriages/terminations of 
pregnancy, current ruptured membranes, known major fetal anomaly or 
abnormal karyotype, or who had received interventions that might modify 
pregnancy outcome (such as aspirin or cervical suture). Full ethical approval 





A research midwife interviewed and examined women who agreed to participate 
at 14-16 weeks’ and again at 19-21 weeks’ gestation. At the time of the 
interview, data were entered into an internet-accessed central database with a 
complete audit trail (MedSciNet). Participants were followed up prospectively, 
with pregnancy outcome data and baby measurements collected by midwives, 
usually within 72 hours of birth. Stringent data monitoring included individual 
checking of all data for each participant, including checks for any transcription 
errors of the lifestyle questionnaire, and using a customised software package 
to detect any systematic data entry errors. 
 
3.3.2 Study Population 
Spontaneous preterm birth was defined as spontaneous preterm labour or 
preterm rupture of membranes at less than 37 weeks’ gestation. Uncomplicated 
pregnancy was defined as a pregnancy with no antenatal obstetric or medical 
complications and resulting in delivery of an appropriately grown, health baby at 
37 or greater weeks’ gestation.   
 
3.3.3 Experimental Samples from SCOPE 
Plasma samples were obtained for women at 20 weeks gestation who 
subsequently had a spontaneous preterm birth (random samples with and 
without PPROM) (n=12), preterm birth with PPROM (n=12), and preterm birth 
without PPROM (n=12). Three distinct control groups (n=12) were obtained, 
matched for centre only.  
 
3.3.4 Samples for Workflow Development   
Venous blood samples were obtained from healthy women with singleton 
pregnancies booked for antenatal care and delivery at the Ninewells Hospital, 
Dundee as part of a previous study (309). Approval was given by the Dundee 
and Manchester Local Research Ethics committees and written informed 
consent obtained for all samples. Plasma samples were prepared by laboratory 
staff at the University of Dundee and transported on dry ice. Non-pregnant 





3.3.5 Comparison of Plasma Sample Preparation Workflows for 
Proteomics 
Replicates of plasma from pregnant women at 20 weeks were either 
immunodepleted of the 14 most abundant plasma proteins using MARS 14 
HPLC column (Agilent, UK) or treated using ProteoMinerTM (Bio-Rad) beads. 
The depleted plasma samples were then further fractionated using a reverse 
phase HPLC column. Following these treatments the plasma samples were 
compared by 1D SDS gels and Bradford protein assay. 
 
3.3.5.1 ProteoMinerTM Beads 
Two plasma replicates of 200µL were mixed with ProteoMinerTM Beads (Bio-
Rad) according to manufacturer’s instructions. Briefly, the beads were prepared 
by rinsing with PBS buffer then mixed with crude plasma on a rotating wheel for 
2 hours at room temperature. Unbound proteins were then removed with wash 
steps. After the appropriate binding and washing steps, proteins were eluted 
using 8M Urea, 1% acetic acid, vortexed and the eluate collected. 
 
3.3.5.2 MARS 14 Immunodepletion  
Plasma (40µL x 2) was depleted of high abundance plasma proteins using the 
MARS 14 Hu column (4.6x100mm) with a 1200 HPLC system (Agilent) with 
thermostat-controlled autosampler and fraction collector. The manufacturer’s 
recommended protocol was followed using proprietary MARS A and B buffers. 
Briefly, 40µL of EDTA plasma was thawed on ice, centrifuged at 10,000g for 10 
minutes at 4°C, then diluted with 120µL Buffer A and injected onto the column 
at 0.125mL/min. UV absorbance was detected at 280nm. A single fraction of the 
flow-through was collected per sample.  
 
All the samples prepared using ProteoMinerTM and MARS 14 were desalted and 
concentrated further using Amicon 10kD molecular weight cut off (Millipore, UK) 
spin columns. Using the spin columns they were buffer-exchanged into 50mM 
AmBic 5% acetonitrile.   
 
Both the MARS 14 and the ProteoMinerTM treated samples were then reduced 




at 60°C for 15 minutes. Iodoacetamide was added to 20mM final concentration 
and the samples placed in the dark for one hour.   
 
3.3.5.3 Bradford Protein Assay 
The concentration of protein in each sample was determined using Bradford 
Protein Assay Reagent (Bio-Rad). Standards (0-1mg/mL) were prepared using 
Bovine Serum Albumin dissolved in ammonium bicarbonate. To 200µL of 
Bradford Protein Assay Reagent, 10µL of sample or standard were added, 
mixed and incubated for 10 minutes at room temperature. Measurements were 
made in triplicate at 595nm using a Spectramax M5 plate reader (Molecular 
Devices, UK). Concentration of samples was calculated by plotting a standard 
curve of concentration against blank-adjusted optical density measurement of 
the standards. 
 
3.3.5.4 Fractionation of samples 
To simplify the complex samples, proteins were fractionated using a 
Macroporous Reversed-Phase C18 Column (mRP-C18, 4.6mm x 50mm, 
Agilent, UK). Mobile phases were A: water + 0.1% Trifluoroacetic acid (TFA); B: 
Acetonitrile + 0.1% TFA. At a flow rate of 0.75mL/min with a gradient of 5-45% 
B over 3.5 minutes, and UV absorbtion at 280nm, fractions were collected every 
0.60 minutes. 
 
3.3.5.5 Sodium dodecyl sulphate (SDS) polyacrylamide gel 
electrophoresis  
Equal volumes of the mRP protein fractions were reduced and denatured by 
dilution 1:10 in distilled water, addition of an equal volume of Lamelli buffer 
(0.125M Tris (pH 6.8), 5% SDS, 50% Glycerol, 25% β- mercaptoethanol, 0.05% 
w/v bromophenol blue) and heating at 90 ºC for 5 minutes. Samples were 
loaded onto a 1.5mm stacking gel and 10% resolving gel with Amersham Full-
Range Rainbow Molecular Weight Markers (12-225 kDa, GE Healthcare, UK). 
Electrophoresis was carried out in Running buffer (25mM Tris-base, 191mM 
Glycine, 3.4mM SDS, pH8.0) using a Mini Protean III Electrophoresis System 





3.3.5.6 Comassie Staining  
To visualise protein bands, gels were stained in Comassie stain (brilliant blue R-
250 10% acetic acid 45% methanol) and rinsed in destain (10% acetic acid 45% 
methanol) with each step carried out with agitation. 
 
3.3.6 MS of samples 
Fractions collected from mRP column ( 3.3.5.4) were dried down in a rotary 
evaporator (Eppendorf, UK). Each fraction was resuspended in 50µl AmBic + 
5% Acetonitrile and Trypsin (Proteomics grade, Sigma) was added to an 
approximate protein: enzyme ratio of 50:1. Tryptic digestion was carried out at 
37°C overnight. 
 
The samples were analysed with HPLC chip-6350 QTOF nano LC-MS platform 
(Agilent) with 60 minute analysis times. Database searching was done with 
Mascot 2.2 (Matrix Science, UK) against the SwisProt Human protein database. 
 
3.3.7 Identification of candidate biomarkers using iTRAQ-based 
relative quantification  
SCOPE plasma samples from preterm labour with ruptured membranes (n=12), 
preterm labour without ruptured membranes (n=12), and corresponding control 
groups (n=12 each) were pooled based on equal volume. Two aliquots of each 
pool were then immunodepleted by the MARS 14 column and subsequently 
desalted on the mRP column (See Figure  3.1). One fraction containing the 
entire elution was collected using the manufacturer’s recommended desalting 
method. The fraction was reduced and alkylated using dithiothreitol (5mM final 
concentration) and iodoacetamide (20mM final concentration) then trypsin 
digested at 1:20 enzyme: protein ratio. Digests were dried down (approx. 80µg 











3.3.7.1 iTRAQ labelling 
The manufacturer’s protocol was followed to label peptides using 8-plex iTRAQ 
Reagents (Isobaric Tags for Relative and Absolute Quantification, Applied 
Biosystems, Warrington, UK). The eight iTRAQ reagents were resuspended in 
50µL isopropanol and transferred to the appropriate sample digests and 
incubated at 23°C for 2 hours. On completion labelled samples were combined 
into one mixture, and then divided into two halves before being dried in the 
rotary evaporator. 
 
3.3.7.2 High pH reverse phase fractionation of iTRAQ labelled peptides 
High pH RP fractionation was performed using a 4.6x150mm Extend SB-300 
HPLC column (Agilent) using the same 1200HPLC system as the mRP column. 
Fresh mobile phases were prepared; A: water + 0.1% ammonium hydroxide; B: 
Acetonitrile + 0.1% ammonium hydroxide (NH4OH). (1mL min, gradient from 5-
40% with 0.35 minute fraction collection). One iTRAQ sample (50% of total) was 
resuspended in 900µL of 5% ACN, 0.1% NH4OH, vortexed hard and centrifuged 
at 16 000g for 5 minutes. The supernatant was removed to a glass vial for 
injection. 80 fractions were collected in total which were dried down completely 
in a rotary evaporator. 
 
3.3.7.3 Analysis of iTRAQ Labelled Samples 
The standard iTRAQ method was followed on the QSTAR Elite (Applied 
Biosystems, UK) with 120min analysis time using the method named 
iTRAQ_120mins. 
 
3.3.7.4 Data analysis  
Data were interrogated using ProteinPilot version 3.0 (Applied Biosystems, 
Warrington, UK) with trypsin as the digest agent and default settings for iTRAQ 
8-plex labelling. Peptide identifications were made using the Paragon algorithm 
(310) searching against the Uniprot Human database. A 95% confidence 
interval cut off was used for significant peptides. False discovery rate was 
calculated by searching all peptide data against a concatenated database 




Relative quantification was carried out using ProteinPilot v3.0 software. An 
average relative quantification ratio is calculated from the unique iTRAQ 
reporter ions associated with the peptides which identify each protein. A 
normalisation factor is applied to each iTRAQ reporter ion ratio to compensate 
for any differences in the amount of starting protein material prior to labelling. 
Relative ratios were calculated against a user defined denominator, in this study 
113 (Term Pregnancy) was used. 
 
3.3.8 Identification of candidate biomarkers using label-free 
methods 
Plasma samples in the SCOPE cohort taken at 20 weeks gestation were 
obtained from 12 women with preterm birth (delivery <37 weeks), 12 controls 
(delivery >37 weeks) and six replicates to assess technical variability. The 40µL 
SCOPE plasma samples were diluted with 160µL MARS buffer. The 24 sample 
cohort was randomly divided with either 1µg/ml or 1.5µg/ml horse myoglobin 
spiked into the samples. These known concentrations were spiked into the 
samples prior to depletion to allow for technical reproducibility to be assessed. 
145µL of each sample was injected onto the MARS 14 column and 
subsequently desalted on the mRP column. Six replicate SCOPE plasma 
samples (R1-6), with no proteins spiked in were also injected randomly as 
another measure of reproducibility (see Table  3-1), and to determine the ability 
of the software to identify quantitative differences in myoglobin levels. The 
samples were then fractionated into six fractions using reverse-phase 
chromatography (mRP-C18, Agilent). Each fraction was trypsin digested and 
run on a LC-QTOF (Agilent) platform to acquire label-free MS data. Analysis 





Table ‎3-1 Sample run on MARS 14 column to demonstrate random 
placement of technical variates 
Sample No. Plate position Outcome Myoglobin Spike  
R1 P1A REPLICATE NONE 
R2 P2A REPLICATE NONE 
1 P1C PT 1µg/mL 
2 P1D PT 1.5µg/mL 
3 P1E T 1µg/mL 
4 P1F T 1.5µg/mL 
5 P1G PT 1µg/mL 
6 P1H T 1µg/mL 
7 P2A T 1.5µg/mL 
8 P2B PT 1.5µg/mL 
9 P2C PT 1µg/mL 
10 P2D PT 1µg/mL 
R3 P2E REPLICATE NONE 
11 P2F T 1µg/mL 
12 P2G PT 1.5µg/mL 
13 P2H PT 1.5µg/mL 
14 P3A T 1.5µg/mL 
15 P3B PT 1.5µg/mL 
R4 P3C REPLICATE NONE 
16 P3D T 1.5µg/mL 
17 P3E T 1.5µg/mL 
18 P3F PT 1µg/mL 
19 P3G T 1.5µg/mL 
20 P3H T 1µg/mL 
R5 P4A REPLICATE NONE 
21 P4B T 1µg/mL 
22 P4C PT 1.5µg/mL 
23 P4D PT 1µg/mL 
24 P4E T 1µg/mL 




3.3.8.1 High pH reverse phase fractionation  
High pH RP fractionation was performed using a 4.6x150mm Extend SB-300 
HPLC column (Agilent) using the same 1200HPLC system as the mRP column. 
Fresh mobile phases were prepared; A: water + 0.1% ammonium hydroxide; B: 
acetonitrile + 0.1% ammonium hydroxide (NH4OH). (1mL min, gradient from 5-
40% with 0.35 minute fraction collection dried down completely in a rotary 
evaporator. 180 fractions (6 from each sample) were collected in total. 
3.3.8.2 Data analysis  
The spectra were analysed using LC-MS Progenesis (Non-Linear Dynamics) to 
detect features that best discriminated sample groups. These features were 
filtered then submitted as targeted MS/MS lists to identify them via database 
searching (Mascot). The data generated from fraction 4 was also analysed to 






3.4 Results  
3.4.1 Comparison of Plasma Sample Preparation Workflows for 
Proteomics 
 
3.4.1.1 Protein fractionation using Reverse Phase HPLC 
To visualise the protein profiles of plasma following MARS 14 depletion or 
ProteoMinerTM beads depletion, samples were fractionated by reverse phase 
chromatography then analysed by SDS-PAGE. The UV chromatogram 
produced by the MARS 14 demonstrated good separation with resolution of 
several peaks (Figure  3.2). The ProteoMinerTM beads chromatogram was 
dominated by a large peak with several other poorly resolved peaks 






Figure ‎3.2 shows mRP chromatograms of plasma prepared with MARS 14 
at UV 280nm 
 
UV chromatogram produced by the MARS 14 demonstrated good separation with resolution of 
several peaks. A flow rate of 0.75mL/min with a gradient of 5-45% B over 3.5 minutes, and UV 
absorption at 280nm, fractions were collected every 0.60 minutes. 
 
Figure ‎3.3 shows mRP chromatograms of plasma prepared with 
ProteoMinerTM beads at UV 280nm 
 
 UV chromatogram produced by the ProteoMinerTM beads dominated by a large peak with 
several others poorly resolved. A flow rate of 0.75mL/min with a gradient of 5-45% B over 3.5 
minutes, and UV absorption at 280nm, fractions were collected every 0.60 minutes. 
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3.4.1.2 Protein Assay Results 
Bradford Assays were performed as described on the individual fractions to 
assess how much protein was present in each sample following depletion. 
Table  3-2 shows the result to compare MARS 14 to ProteoMinerTM beads. 
Although the capacity of the ProteoMinerTM beads was five times greater than 
the MARS columns, the yields were very similar.  
  
Table ‎3-2 Comparison of amount of protein (µg) in each fraction using 
MARS depletion and ProteoMinerTM beads depletion 
mRP 
Fraction 
Amount of Protein (µg) MARS 
14 
 
Amount of Protein (µg) ProteoMinerTM 
Beads 
1 0 0 
2 0 0 
3 6 6 
4 25 50 
5 50 100 
6 50 50 
7 12 12 
8 25 12 
Total 168 230 
 
3.4.1.3 SDS Gels to compare MARS 14 and ProteoMinerTM Beads  
When visualised on protein gels the two sets of samples showed completely 
different band patterns (Figure  3.4 and Figure  3.5) highlighting the fact they had 






Figure ‎3.4 SDS gel of proteins present following depletion using MARS 14. 
Desalt is the protein elution collected in the total sample prior to 
fractionation 
 
Figure ‎3.5 SDS gel of proteins present following depletion using 
ProteoMinerTM beads. Desalt is the protein elution collected in the 





3.4.1.4 MS/MS of fractions  
94 proteins were identified on MS/MS following depletion with MARS 14 and 85 
proteins following depletion with ProteoMinerTM beads. Appendix A lists the 
proteins identified following depletion with MARS 14 and ProteoMinerTM beads.  
 
Of the 14 proteins which should have been depleted by the MARS column, 
eight were still present in the ProteoMinerTM treated plasma. These were some 
of the most abundant proteins and therefore visualisation of lower abundance 
proteins was more challenging. It was noted that most of the proteins identified 
are found at 100µg/mL or higher in plasma. C-reactive protein was an example 
of a protein which circulates at a lower level (<10µg/mL in human plasma) and 
was observed in both methods. However, the concentration of proteins 
observed was remote from the concentration associated with likely biomarkers 
(pg/mL – ng/mL).  
 
Overall, the MARS treated plasma showed more bands, a better reversed 
phase fractionation, and more protein identifications when analysed by mass 
spectrometry. Table  3-3 summarises the differences between MARS 14 





Table ‎3-3 Summary of properties of MARS depletion and ProteoMinerTM 
beads treatment 
 MARS 14 
 
ProteoMinerTM 
Technology Immobilised Polyclonal 
 
Hexameric Peptide Library 
Format HPLC column 
 
Microcentrifuge tubes 
Plasma capacity 30µL to 40µL  
 
200µL to 1mL 
Workflow Automated procedure, 
sequential runs on HPLC 
 
Manual processing of many 
samples simultaneously 
Reproducibility Very good 
 
Untested 
Approx. cost per sample £10 £3 
Approx. yield 30µL plasma gives 150µg 
protein 
 







Ideal for protease digestion 
Notes Depletion of albumin-
bound proteins 
 
No quantification on 








3.4.2 iTRAQ quantitative analysis of term versus preterm samples 
3.4.2.1 iTRAQ sample preparation 
When the eight samples were MARS depleted and desalted on mRP column 
the UV chromatograms overlay almost perfectly (see Figure  3.6 and Figure 3.7). 
This demonstrated that there was little technical variation introduced at this 
stage of the workflow.  The high pH reverse phase HPLC chromatogram 
showed an even separation of the labelled peptides over the 80 fraction 
collection window (see Figure  3.8). 
 














3.4.2.2 Identification of proteins  
Following MS/MS of the iTRAQ labeled plasma, 243 high confidence protein 
identifications were identified; with relative quantification data available for 117 
of these (see Appendix B). 






3.4.2.3 Normalisation factor 
ProteinPilot data were filtered to look for proteins with good technical 
reproducibility and good reproducibility between two controls. Only when 
consistent quantification was observed was the peptide quantification data 
included within the analysis.  
 
Table  3-4 shows the normalisation factors applied by ProteinPilot to the iTRAQ 
reporter ions. The majority of proteins in a sample would be present at an equal 
abundance and therefore it should equal 1. It can be seen that labels 115 and 
119 had unacceptable normalization factors so were therefore removed from 
subsequent analysis. This still allowed for technical reproducibility to be 
assessed but limited the number of cases which could be analysed. 
 
Table ‎3-4 ProteinPilot normalisation factors for iTRAQ reporter ions 
Ratio Comparative groups Normalisation factor 
114:113 Term:Term 1.2379 
115:113 Preterm with PRROM:Term 0.3322 
116:113 Preterm with PPROM:Term 1.1123 
117:113 Term:Term 1.4383 
118:113 Term:Term 1.1251 
119:113 Preterm no PPROM:Term 0.1790 
121:113 Preterm no PPROM:Term 1.0432 
 
3.4.2.4 Quantitative data 
An example of a peptide assigned to anti-thrombin III and its iTRAQ 
quantification data is shown in Figure  3.9. The relative intensities of the reporter 
ions can be used to demonstrate the relative quantification of each peptide 
identified in relation to each sample pool. The statistical p value calculated by 
ProteinPilot tested the null hypothesis that the protein was unchanged between 
the sample and the reference group (113). The data were interrogated to 
identify fold changes <0.8 and >1.2 in proteins between control and case 





Figure ‎3.9 Example of a peptide assigned to anti-thrombin III and its iTRAQ quantification data 
 91 
  
3.4.2.5 Technical replicates 
An example of a good technical replicate was seen when comparing two pools 
from the same group. For example, 113 and 114 were proteins both from the 
same term pregnancy control group. It can be seen in Table  3-5 that there was 
no significant difference in the ratio of the protein apolipoprotein C-II in the two 
samples labeled with 113 and 114. Another example is seen with complement 
C4-B and 117 and 118 as the ratios to 113 were very similar. 
 
Table ‎3-5 Example of good technical replicate 

















































3.4.2.6 Proteins of interest 
3.4.2.6.1 Term pregnancy versus Preterm birth with PPROM 
When comparing the iTRAQ data from women who delivered at term compared 
to women who experienced preterm birth with PPROM, there were five proteins 
with significant differences between the groups (Table  3-6).  
 





















































































3.4.2.6.2 Term pregnancy versus preterm birth without PPROM 
The comparison between iTRAQ data from term pregnancy and preterm birth 
without PPROM identified nine candidate proteins (Table  3-7). 
 




















































































































































3.4.2.6.3 Term pregnancy versus spontaneous preterm birth 
Comparison of iTRAQ data for term pregnancy vs all preterm, (with and without 
PPROM) identified, one protein, Fetuin-B, as being different between groups 
(Table  3-8). 
 
Table ‎3-8 Protein of interest for term pregnancy versus spontaneous 
preterm birth 
Comparison Term:Term Preterm with 
PPROM:Term 































3.4.3 Results of label-free methods 
 
3.4.3.1 Label-free sample preparation 
When the six replicate samples (see  3.3.8) were MARS depleted and desalted 
on the mRP column, the UV chromatograms overlayed almost perfectly. This 
demonstrated that minimal variation was introduced at this stage of the 
workflow (see Figure  3.10 and Figure  3.11). However, the large biological 
variation of the samples can be seen by the difference in the poor overlay of the 
MARS and mRP chromatograms of the term and preterm plasma samples (see 
Figure  3.12 and Figure  3.13). Figure  3.14 demonstrates the mRP fractionation 
of a preterm sample into 6 equal fractions.  
 




Figure ‎3.11 mRP UV chromatograms of the replicate samples (n=6) 
 
 






Figure ‎3.13 mRP UV chromatograms of 20 week plasma samples (n=24) 
 
 







3.4.3.2 Identification of proteins  
LC-MS Progenesis was used to detect features that best discriminated between 
the sample groups. These features were filtered then submitted as targeted 
MS/MS lists to identify them via database searching (Mascot). If a protein was 
different between groups then all of the peptides from that protein should 
behave the same. In the myoglobin control experiment, 100% of the peptides 
identified from myoglobin discriminated between the sample groups (see 
Table  3-9). The preterm birth versus term birth comparison demonstrates that 
only a small number of the peptides identified from each protein were changed 
and therefore these are more likely to represent background noise than actual 
changes in protein abundance (Table  3-10). 




Total peptides  
Myoglobin (horse)  3  3  
Complement 
component C8B  
1  17  
 
Table ‎3-10 Identifying peptides between preterm and term birth 
 Identifying peptides  Total peptides  
Beta-2-glycoprotein 
1  
2  18  
Complement 
component C6  
1  27  
Pregnancy-specific 
glycoprotein-7  
1  3  
Ceruloplasmin  1  59  
Complement 
component C4  
3  86  
Inter-alpha-trypsin 
inhibitor heavy chain 
2  
1  34  
Angiotensinogen  1  16  
Complement 
component C5  






The ultimate goal of this plasma biomarker discovery was to accurately quantify 
thousands of proteins within a small number of well-characterised clinical 
samples. Given the high dynamic range and complexity of the plasma 
proteome, the current proteomics technology forces compromises between 
proteome penetration and sample number. In the proteomics community, there 
is no consensus on how to achieve this balance. Immunodepletion of highly 
abundant plasma proteins is part of most plasma biomarker workflows. Whilst 
the performance of immunodepletion columns has been shown to be 
reproducible (311), their limited loading capacity and the complexity of the 
depleted plasma leaves significant scope for the development of alternative 
methods to enrich for low abundance proteins.   
 
ProteoMinerTM (PM) beads have, to date, mostly been used for 2D gel 
applications. Sihlbom et al (312) demonstrated that the beads are an efficient 
and simple prefractionation method to increase the possibility of penetrating low 
abundance proteins not accessible before depletion. The results from the 
analyses presented here, however, indicate that the ProteoMinerTM beads do 
not represent an improved sample preparation workflow compared to other 
immunodepletion methods. Advantages of the beads include their high loading 
capacity, single use (which avoids the potential for contamination between 
samples), efficient parallel processing of samples, and compatibility with all 
major downstream protein analysis techniques. 
 
Disadvantages of the PM beads include the fact that they have uncharacterised 
reproducibility, and their mode of action makes it impossible to predict what 
proteins will bind to the beads and with what affinity. Their mechanism of action 
means that any proteins that saturate the beads (high abundance or high affinity 
ones) will elute at equal levels across all samples so any biological differences 
could be missed (false negatives). As some proteins will not bind to the beads, 
these proteins will also be lost potentially leading to additional false negative 
findings. The current study has demonstrated that plasma treated with the PM 
beads still contained many of the most abundant proteins that the MARS-14 
column had been able to remove, especially albumin. This makes it less likely 




MARS 14 is widely used and known to be reproducible (296). There are 
however two drawbacks which need to be acknowledged. The first is the 
removal of albumin which will lead to the co-depletion of proteins and bioactive 
factors bound to this carrier. The second is the limited capacity of the column 
which means that only small volumes of plasma can be processed. The lower 
cost and higher capacity of the PM beads are however outweighed by their 
inferior ability to remove high abundance proteins and therefore make lower 
abundance plasma proteins available for MS analysis. 
 
The iTRAQ data has demonstrated that a modest number of proteins can be 
identified and quantified using this workflow. From the normalisation factors, it 
can be ascertained that the iTRAQ labelling was not successful in all pooled 
samples. This was demonstrated by the MARS and mRP chromatograms which 
showed almost identical amounts of protein present in the samples prior to 
labelling. iTRAQ labelling failure appears to be a sporadic issue noted by many 
users. Unfortunately, by removing two samples there were no valuable technical 
duplicates for the two preterm groups, which limit the significance of any 
observed differences.   
 
Using pooled samples is a common feature of proteomic experiments and has 
also been reported in microarray/genomics experiments (313). It would be 
difficult to perform a 12 vs 12 individual sample analysis using the iTRAQ 
technique due to high instrument time, expense and issue with quantifying 
across separate experiments. So given the choice, we are more likely to 
demonstrate change with pooled samples of 12, as opposed to 2 or 3 individual 
samples from each group. It is also likely that a pool of 12 will be big enough for 
one outlier sample to not skew the pool.   
 
As with all biomarker studies, the false positive rate can be very high, therefore 
conclusions cannot be drawn too quickly. The limitations of this study are that it 
is a single experiment and so would need to be repeated two or three more 
times to combine and compare the data. It can be seen however, that although 
there are 15 statistically significant protein differences, the small fold changes 
are such that demonstrating a clinical significance would be unlikely. Table  3-11 
shows the names of the proteins identified as being different between the three 
comparison groups. The proteins found are generally related to systemic 
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inflammation and it is likely that these will be less helpful due to being be non-
specific. 
 
Table ‎3-11 Proteins identified in each of the three comparison groups 
PTB-PPROM vs Term PTB-IM vs Term Preterm vs Term 
Hemopexin 
 
Complement factor B         Fetuin-B         
Beta-2-glycoprotein 1     
     
Alpha-1B-glycoprotein          
Coagulation factor XII        
  
Fibrinogen beta chain          
Alpha-1-antichymotrypsin         Complement component 
C6         
 
Complement C2         
 
Protein AMBP          
 C4b-binding protein alpha 
chain         
 
 Apolipoprotein C-III       
 
 
 Fibrinogen gamma chain 
 
 
 Disintegrin and 
metalloproteinase domain 




Although technically a good study, the label-free methods failed to detect any 
proteins which could show a difference between the preterm birth and term birth 
women. The ability to detect a 1.5x fold change in an exogenous protein at 
1µg/ml was however, convincingly demonstrated. It is therefore unlikely that 
there are any endogenous proteins that discriminate term and preterm birth at a 
concentration above ~1µg/ml in 20 week plasma samples. This fits with 
previous studies which fail to identify any significant biochemical biomarkers for 
prediction of preterm birth and is in contrast to pre-eclampsia where dozens of 
candidate markers have been identified e.g. PlGF, PP13 (282, 301).  
 
One of the potential issues that this study highlights is that the preterm birth and 
term birth samples used were actually quite similar. When the gestation of the 
samples is plotted (Figure  3.15) it can be seen that there may be only a two-
week difference in gestation between cases and controls. Therefore a large 
biochemical difference would be very difficult/impossible to identify at 20 weeks. 
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This difference may be clinically very relevant however, and may be the 
difference between needing neonatal care or not. 
 
Figure ‎3.15 Delivery gestation of women from Proteomics studies 
 
 
Given access to a larger number of samples of the early preterm birth cohort I 
may have been able to biochemically discriminate them from the controls. The 
fact that over half of the samples were late preterm birth may have made the 
sample groups too similar. It is not worth doing any further proteomic analysis 
with this cohort as there is probably too much overlap.  
 
With pre-eclampsia, adding biochemical markers adds strongly to the prediction 
algorithm e.g. PlGF; however no biochemical marker to add to a preterm birth 
clinical algorithm has been identified. Another way of assessing biochemical 
differences is to look at a known number of low abundance proteins, such as, 
cytokines, rather that looking at the global proteome, and the next chapter of my 






















4 Maternal Plasma Cytokines as Predictors of Spontaneous 
Preterm Birth 
4.1 Introduction 
In order to predict and prevent preterm birth, and minimise the adverse neonatal 
outcomes associated with prematurity, it is essential to understand the causes 
of preterm labour. The biomolecular mechanisms leading to labour, both 
preterm and term, are not well understood. Although PTL and labour at term 
share a common terminal pathway, comprising uterine contractions, cervical 
dilation ± rupture of membranes, research shows that PTL is induced by 
significantly different factors than labour at term (23).  
 
Labour in humans results from a complex association of fetal and maternal 
factors, although the exact mechanism still remains uncertain (23). The human 
placenta plays a major role in pregnancy and the cascade of labour processes 
are activated via placental mediators exerting endocrine, paracrine, and 
autocrine actions (314). Whilst some of the mediators are involved in 
myometrial activation and preparation, others are involved in myometrial 
stimulation leading to delivery (315).  
 
In the early stages of pregnancy, myometrial substances, like progesterone, 
nitric oxide, and relaxin, contribute to the retention of the pregnancy (314). At 
late stages of gestation, fetal hypothalamus maturation signals act on the 
placenta causing the production of hormones, including CRH, in an endocrine 
manner; the signals then enhance the production of more hormones, such as 
oestrogens and neuropeptides, that contribute to cervical ripening and uterine 
contractility (316). These molecules act directly on the myometrium through 
specific receptors, while cytokines and multiple growth factors are also 
produced, inducing prostaglandin production which additionally contributes to 
labour (314).  
 
In situations leading to preterm labour, as in maternal stress, overdistension, 
haemorrhage and fetal infection, it is thought that cytokines trigger placental 
signalling sooner, thus leading to preterm birth (314). Infection/inflammation 
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predominates as a cause of early preterm birth, whereas maternal or fetal HPA 
axis activation is more commonly associated with late preterm birth after 32 
weeks gestation (18). Goldenberg et al. reported that up to 80% of women who 
deliver before 30 weeks of gestation have evidence of bacterial infection of the 
amniotic fluid and/or membranes, compared with only 30% of those who deliver 
after 37 weeks gestation (26). 
 
The mechanisms by which intrauterine infections lead to preterm labour are 
related to activation of the innate immune system (23). The cervix, fetal 
membranes and mucus plug serve to provide a mechanical and chemical 
barrier to prevent ascending infection from accessing the genital tract. However, 
when these barriers fail, microorganisms are recognised by pattern-recognition 
receptors, for example toll-like receptors, which in turn elicit the release of 
proinflammatory chemokines and cytokines—such as interleukin-8, interleukin-
1β, and tumour necrosis factor-α. Microbial endotoxins and proinflamatory 
cytokines stimulate the production of prostaglandins, other inflammatory 
mediators, and matrix-degrading enzymes. Prostaglandins stimulate uterine 
contractility, whereas degradation of extracellular matrix in the fetal membranes 
leads to PPROM (23, 26, 317). An understanding of the innate immune system 
may enable the cascade of events in preterm labour to be arrested early on, 
which may improve our ability to target specific subgroups for the prevention of 
preterm birth. 
 
Inflammation is the mechanism by which the body responds to the presence of 
infective and non-infective insults. It allows for the destruction of the invading 
pathogen whilst preserving normal tissue integrity and function. Inflammation is 
mediated through the interaction of a complex network of pro-inflammatory 
(Th1) and anti-inflammatory (Th2) cytokines and other immunomodulators 
(151). Pregnancy is thought to be predominantly a Th2 dominant state allowing 
maternal regulation, but preventing rejection of the semi-allogenic fetus. Nearer 
term there is a gradual shift towards a Th1 state which culminates in labour and 
delivery. An early shift to Th1 activity is thought to be involved in preterm 
delivery and preterm prelabour rupture of membranes (318). 
 
Cytokines are pleiotropic glycoproteins which help to regulate all biological 
processes, and in particular are involved in immune regulation. They generally 
have a molecular mass of less than 30 kDa and are structurally characterised 
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as belonging to one of four groups: the haematopoietin family, the interferon 
family, the chemokine family, and the tumour necrosis family. Cytokines can 
mediate their biological effects at picomolar concentrations because of their 
high affinities. Cytokines may act on the cells that secrete them (autocrine 
action), on nearby cells (paracrine action), or in some instances on distant cells 
(endocrine action). Their pathways have been extensively investigated within 
maternal and fetal tissues in order to ascertain a possible link between 
inflammation and spontaneous preterm labour (319-327). Although most studies 
have examined these biomarkers after the onset of labour or rupture of 
membranes, several have examined their role as systemic inflammatory 
biomarkers, studying plasma or serum cytokines (86, 328-334) in the prediction 
of spontaneous preterm labour.  
 
Figure  4.1 illustrates the complicated network of cytokine and chemokine 
signalling. This interdependent relationship makes isolating the roles of 
individual cytokines and chemokines hard, and their effects complicated to 
understand and predict. 
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Figure ‎4.1 Cytokine network depicting the interaction of various cell types. 






4.1.1 Proinflammatory cytokines and preterm labour 
There is strong evidence to support a role for cytokines in the initiation of 
inflammation/infection-induced preterm labour (32, 106, 336-344). The most 
commonly studied have been the proinflammatory cytokines IL-1β, TNF-α and 
IL-8. It is thought that during the course of ascending intrauterine colonisation, 
microorganisms may reach the decidua, where they can stimulate a local 
inflammatory reaction and the production of proinflammatory cytokines and 
inflammatory mediators (platelet-activating factor, prostaglandins, leucotrienes, 
reactive oxygen species, NO, amongst others) (23). If labour is not started from 
this inflammatory process, then microorganisms may also cross intact 
membranes into the amniotic cavity, where they can stimulate the production of 
other inflammatory mediators by resident macrophages and other host cells. 
Those microorganisms that have gained access to the fetus may elicit a 
systemic inflammatory response syndrome, characterised by increased 
concentrations of IL-6 (345, 346) and other cytokines (347), as well as cellular 
evidence of neutrophil and monocyte activation (348). 
 
IL-1 was the first cytokine to be implicated in the onset of spontaneous preterm 
labour associated with infection (349). Evidence in support of the participation of 
IL-1 is shown in Table  4-1. 
 
Table ‎4-1 Evidence to demonstrate IL-1 is associated with preterm labour 
Study Evidence 
Romero et al 
(1989)(350)  
IL-1 is produced by human decidua in response to bacterial 
products 
Romero et al 
(1989)(351) 
IL-1 stimulates prostaglandin production by human amnion 
and decidua 
Romero et al 
(1989)(352) 
Increased IL-1 concentration and bioactivity in the 
amniotic fluid of women with preterm labour and infection 
Sadowsky et al 
(2003)(353) 
IL-1 stimulates myometrial contractions 
Romero et al 
(1991)(354) & 
Romero et al 
(1992)(355) 
Administration of IL-1 to pregnant animals induced 
preterm labour and preterm birth which could be blocked 




Similarly, the evidence supporting the role of tumour necrosis factor-alpha 
(TNF-α) in the mechanisms of preterm parturition is shown in Table  4-2. 
 
Table ‎4-2 Evidence to demonstrate TNF-α‎is‎associated‎with‎preterm‎
labour 
Study Evidence 
Romero et al (1998) (28) TNF-α stimulates prostaglandin 
production by the amnion, decidua, and 
myometrium 
Casey et al (1989) (356) & Romero et al 
(1991) (357) 
Human decidua can produce TNF-α in 
response to bacterial products 
Romero et al (1989) (358) AF TNF-α bioactivity and 
immunoreactive concentrations are 
elevated in women in preterm labour 
and with intra-amniotic infection 
Romero et al (1989) (358) In women with PPROM and intra-
amniotic infection, TNF-α 
concentrations are higher in the 
presence of labour 
Chwalisz et al (1994) (359) TNF-α application on the cervix induces 
changes that resemble cervical ripening 
Hirsch et al (2006) (360) TNF-α is involved in the mechanisms of 







4.1.2 Anti-inflammatory cytokines and preterm labour 
A key cytokine involved in the maintenance of pregnancy is IL-10. Compared to 
first and second trimester tissues, the production of IL-10 in the placenta is 
significantly reduced at term prior to labour. This suggests that the reduction of 
IL-10 is a physiological event that favours an inflammatory state around the time 
of the onset of labour (361). IL-10 has been shown to be reduced in the 
placental tissues of pregnancies complicated by preterm labour and 
chorioamnionitis compared to normal controls (362) and in animal models, the 
administration of IL-10 has been associated with improved pregnancy outcome 
(363). 
 
4.1.3 Multiplex Technology 
Conventionally, enzyme-linked immunosorbent assays (ELISAs) have been the 
technique used to measure protein concentrations in biological samples. 
However, this method is time consuming and only allows for the analysis of a 
single cytokine using a minimum of 200µL of sample. Over the last decade, 
multiplex cytokine technologies have become readily available. These allow 
multiple analytes to be measured in a smaller volume of biological sample. 
 
Bio-Plex ProTM Assays are magnetic bead-based multiplex assays designed to 
measure multiple members of the diverse group of proteins in a minimal volume 
of matrix such as serum, plasma, tissue culture supernatant and other biological 
fluids. 
 
The Bio-Plex ProTM suspension is built around three principles: 
1. Fluorescently dyed microspheres (beads) each with a distinct colour 
code to permit discrimination of individual tests within a multiplex 
suspension. 
2. A flow cytometer with two lasers and optics to measure the different 
molecules bound to the surface of the beads 
3. A high-speed digital signal processor that efficiently manages the 
fluorescence data. 
 
The assay principle (Figure  4.2) is to have antibodies directed against the 
intended cytokine coupled to the beads. The coupled beads react with the 
110 
  
sample containing the biomarker of interest. After a series of washes to remove 
unbound protein, a biotinylated detection antibody is added to create a 
sandwich complex. The final detection complex is formed with the addition of 
streptavidin-phycoerythrin (SA-PE). Phycoerythrin serves as a fluorescent 
indicator, or reporter. 
 
Figure ‎4.2 Schematic representation of an immunoassay sandwich-based 







The contents of each well are then drawn up into the array flow system. A red 
(635nm) laser illuminates the fluorescent dyes within each bead to provide 
identification. At the same time, a green (532nm) laser excites PE to generate a 
reporter signal. A data processor manages the output and presents data as 




4.2 Aim of this study 
Although multiple inflammatory mediators including cytokines have been 
evaluated before in women with a previous preterm birth, they have not been 
specifically studied in a nulliparous, low risk population. The aim of this study 
was therefore to examine a panel of cytokines in maternal plasma taken at 20 
weeks gestation to discover a marker, or combination of markers, for the 
prediction of spontaneous preterm birth less than 35 weeks gestation. Maternal 
blood is a readily accessible source, which is far easier to collect than amniotic 






4.3.1 Patient plasma samples 
EDTA-plasma from women at 20±1 week gestation who had uncomplicated 
pregnancies (controls) or who subsequently delivered prematurely were 
obtained from the SCOPE biobank (Auckland, New Zealand) (See  3.3.1.1). 
Blood was collected by venepuncture into BD EDTA-Vacutainer®, placed on ice 
and centrifuged at 2400 x g for 10 minutes at 4°C. Plasma was stored at -80°C 
within 4 hours of collection. Sample collection and storage conditions were 
closely regulated for all samples. Plasma samples were defrosted on ice and 
always maintained below 4ºC during experiments. 
 
4.3.2 Study population 
Spontaneous preterm birth was defined as spontaneous preterm labour or 
preterm rupture of membranes at less than or equal to 34+6 weeks’ gestation. 
Uncomplicated pregnancy was defined as a pregnancy with no antenatal 
obstetric or medical complications and resulting in delivery of an appropriately 
grown, healthy baby at 37+0 or greater weeks’ gestation. 
 
4.3.3 Experimental samples from SCOPE 
Plasma samples were obtained for women in the southern hemisphere cohort of 
the SCOPE biobank who subsequently had a spontaneous preterm birth 
(n=40), of which n=21 were preterm birth with PPROM (PTB-PPROM), and 
n=19 were preterm birth with intact membranes (PTB-IM). One control group 




4.3.4 Multiplex analysis 
For this study, cytokine analysis was performed using Bio-Plex ProTM Assays for 
cytokine, chemokine and growth factors (BioRad Laboratories, Hemel 
Hempstead, UK). The samples were run according to manufacturers 
instructions on a Luminex-100 cytometer (Luminex Corporation, Austin, Texas), 
equipped with STarStation Software (Version 2.0: Applied Cytometry Systems, 
Dinnington, UK). The kits were available as pre-determined panels including 
pre-mixed beads, detection antibodies and standards enabling a considerable 
time saving.  
 
Twenty-seven cytokines, chemokines and growth factors were analysed during 
the study. Table  4-3 shows the different assays performed. 
 
Table ‎4-3 Bio-PlexTM Pro Human Cytokine Standard 27-Plex Group 1 
IL-1β IL-10 IFN-γ 
IL-1ra IL-12p70 IP-10 
IL-2 IL-13 MCP-1 
IL-4 IL-15 MIP-1α 
IL-5 IL-17A MIP-1β 
IL-6 Eotaxin PDGF-BB 
IL-7 Basic FGF RANTES 
IL-8 G-CSF TNF-α 
IL-9 GM-CSF VEGF 
 
The cytokine standards were reconstituted and serially diluted. The multiplex 
bead working solution was prepared. Sample dilution was undertaken at 1:2. 
The 96-well plate was pre-soaked with the assay buffer and then removed by 
vacuum filtration. This was repeated using the multiplex bead working solution 
and subsequently the assay buffer. The plasma sample (50µL) was transferred 
into each well, covered with foil and incubated at room temperature with 
shaking at 300 RPM for 30 minutes. At the end of the first incubation, the buffer 
was removed by vacuum filtration and each well underwent three washes with 
100µL assay buffer ensuring vacuum filtration to remove buffer after each wash. 
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Detection antibody solution (25µL) was added to each well, covered and 
incubated for 30 minutes at room temperature, with shaking at 300 RPM. The 
plate was washed three times with 100µL assay buffer again with vacuum 
filtration after each wash. Streptavidin-PE (50µL) was added to each well, 
covered and incubated for 10 minutes at room temperature, with shaking at 300 
RPM. Buffer was removed by vacuum filtration and the plate washed 3 times 
with assay buffer, with vacuum filtration each time. The beads were 
resuspended in 125µL assay buffer and incubated at 110 RPM for 30 seconds. 
The plate was then read on the Bio-Plex Pro TM system. 
 
Concentrations in ng/mL were calculated from the standard curves using 4PL 
logistic regression with Bio-Plex ProTM software.  
 
4.3.5 Data analysis  
Data analysis was performed using GraphPad Prism Version 6.04, USA. Mann-
Whitney U tests were performed as the Shapiro-Wilk test demonstrated a non-
normal distribution of data. The differences were tested to a significance of 
P<0.05. 
 
Another method of analysing the cytokine data is Bayesian network formalism. 
This involves a statistical procedure that can characterise a network of variables 
(in this case cytokines) and represent their interactions as a directed acyclic 
graph (DAG). The connections between the nodes (variables) are known as 
‘edges', and imply causal directionality, i.e. the status (relative concentration, in 
this case) of a downstream cytokine is dictated by that of its immediate 
upstream ‘parent(s)' These models are very useful in exploring the complex 
nature of cytokine networks, given that they can also capture synergistic and 
antagonistic interactions at nodes having more than one parent. Computational 
machine-learning-based methods undertake the inference process. In order to 
establish a prior cytokine network in this target set, a seed network is learned 
from literature-mining algorithms. Such prior knowledge speeds up the analysis 
and yields more robust networks, while minimising the risk of introducing bias. 
In this study, all 27 cytokines were set as random variables. Their interactions in 




Support vector machines (SVM) are a way of classifying the data to know which 
cytokines are the most important when deciding whether a woman had a 
preterm birth or not. It is computer based and was done with a 5-fold cross 






Table  4-4 shows the 40 case samples with gestation of delivery and membrane 
status. The control samples were deliveries >37 weeks. 
Table ‎4-4 Gestation of delivery and membrane status for samples in 
preterm birth group 
Sample ID Gestation 
of delivery 
(weeks) 




1324 34+2 Intact 1175 34+1 PPROM 
1222 25+5 Intact 1350 24+3 PPROM 
1218 34+1 Intact 1336 34+5 PPROM 
1347 32+6 Intact 3103 34+3 PPROM 
2896 22+5 Intact 3308 25+3 PPROM 
3357 31+3 Intact 4019 33+3 PPROM 
2959 25+2 Intact 3834 26+6 PPROM 
3038 24+3 Intact 4689 34+3 PPROM 
3948 33+5 Intact 323 34 PPROM 
11 32+1 Intact 885 34+4 PPROM 
269 32+3 Intact 1177 32+1 PPROM 
869 23 Intact 1196 33+5 PPROM 
814 31+3 Intact 1455 26+5 PPROM 
1373 34+5 Intact 1573 31+6 PPROM 
3342 28+1 Intact 2067 34 PPROM 
2923 32+1 Intact 2558 32+5 PPROM 
1294 32+5 Intact 3234 33+2 PPROM 
3567 28+4 Intact 3003 32+3 PPROM 
1986 34+1 Intact 2630 33 PPROM 
   2910 33+5 PPROM 
   3473 33+3 PPROM 
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Table  4-5 compares the baseline characteristics of the 40 cases and 40 controls 
in this cohort. 
Table ‎4-5 Baseline characteristics of cases and controls 


























































































































Smoking status at 15 weeks 
Never smoked 
Smoked pre-pregnancy, quit 
before pregnancy 
Smoked in pregnancy, quit 





























































































































In total 27 cytokines were measured. Cytokines were compared between term 
or preterm birth, term or preterm birth with intact membranes (PTB-IM) and term 
or preterm birth with PPROM (PTB-PPROM). Not all samples recorded cytokine 
levels that were detectable therefore these were recorded as 0ng/mL. Table  4-6 
compares the median and range of the 27 cytokines among the term controls, 




Table ‎4-6 Associations between maternal plasma cytokine median (range) 
concentration (ng/mL) and spontaneous preterm birth 


































































































IL-13 4.61  
(1.46-33.97) 





































































































































4.4.1 Term versus preterm labour 
No cytokines showed a statistically significant difference between the term 
controls and the spontaneous preterm birth group. However, with the majority of 
the cytokines a downward trend was noted in the spontaneous preterm birth 
group as compared to the term group. 
 
Cytokine P value Cytokine P value 
IL-1b 0.7250 Eotaxin 0.7430 
IL-1ra 0.8764 Basic FGF 0.4507 
IL-2 0.8909 G-CSF 0.2567 
IL-4 0.1544 GM-CSF 0.5943 
IL-5 0.2276 IFN-g 0.6237 
IL-6 0.9447 IP-10 0.3819 
IL-7 0.1734 MCP-1 0.7143 
IL-8 0.3613 MIP-1a 0.5448 
IL-9 0.5134 MIP-1b 0.3588 
IL-10 0.4032 PDGF-BB 0.5512 
IL-12 0.3463 RANTES 0.2629 
IL-13 0.3293 TNF-a 0.8764 
IL-15 0.7561 VEGF 0.4251 
IL-17A 0.7904   
 
An example of the major pro- (IL-1b, IL-6, TNF-α) and anti-inflammatory (IL-10) 




Figure ‎4.3 Charts demonstrate concentration (ng/mL) of cytokine (a) IL-1b 






















































4.4.2 Term versus preterm birth with preterm prelabour rupture of 
membranes 
As no cytokines were significant between the term and preterm groups, a 
further comparison was done between those with preterm prelabour rupture of 
membranes versus women who delivered >37 weeks. No statistically significant 
difference was found between the two groups. 
 
Cytokine P value Cytokine P value 
IL-1b 0.6495 Eotaxin 0.3655 
IL-1ra 0.5792 Basic FGF 0.4140 
IL-2 0.5852 G-CSF 0.7699 
IL-4 0.8470 GM-CSF 0.1582 
IL-5 0.6316 IFN-g 0.6316 
IL-6 0.3998 IP-10 0.2797 
IL-7 0.5877 MCP-1 0.2274 
IL-8 0.5049 MIP-1a 0.5708 
IL-9 0.1996 MIP-1b 0.5708 
IL-10 0.6493 PDGF-BB 0.7782 
IL-12 0.4658 RANTES 0.2380 
IL-13 0.4969 TNF-a 0.4582 
IL-15 >0.9999 VEGF 0.7041 





4.4.3 Term versus preterm birth with intact membranes  
A third subgroup comparison was done between those with preterm birth with 
intact membranes and women who delivered >37 weeks. Four cytokines 
showed a statistically significant difference (p<0.05) between the term group 
and the preterm birth with intact membranes group IL-4, IL-7, IL-13 and G-CSF 
(Figure  4.4). 
 
Cytokine P value Cytokine P value 
IL-1b 0.4224 Eotaxin 0.6082 
IL-1ra 0.4307 Basic FGF 0.1009 
IL-2 0.7224 G-CSF 0.0422* 
IL-4 0.0407* GM-CSF 0.5841 
IL-5 0.0600 IFN-g 0.2935 
IL-6 0.5782 IP-10 0.8011 
IL-7 0.0150* MCP-1 0.5586 
IL-8 0.0601 MIP-1a 0.2146 
IL-9 0.8343 MIP-1b 0.5111 
IL-10 0.1790 PDGF-BB 0.2093 
IL-12 0.0522 RANTES 0.7012 
IL-13 0.0454* TNF-a 0.4307 
IL-15 0.8980 VEGF 0.1563 
IL-17A 0.2930   





Figure ‎4.4 Charts demonstrate concentration (ng/mL) of cytokine (a) IL-4 
(b) IL-7 (c) IL-13 and (d) G-CSF in each preterm with intact 


















































4.4.4 Ratios between pro- and anti-inflammatory cytokines  
To interrogate the data further I have also looked at the ratios between the 
major pro- (IL-6) and anti-inflammatory (IL-10) cytokines in the three groups of 
spontaneous preterm birth, preterm birth with preterm prelabour ruptured 
membranes (PTB-PPROM) and preterm birth with intact membranes (PTB-IM) 
when compared with term controls. Again no statistical significance was seen 
between the groups.  
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4.4.5 Bayesian Network Formalism 
Figure  4.5 shows the cytokine network for term birth and Figure  4.6 the cytokine 
network for spontaneous preterm birth. Interestingly, despite the analysis being 
done independently it can be seen that the overall pathway for the two different 
populations is the same. The main drivers for both of the networks are IL-1β 
and IL-15 with multiple interactions downstream from them. The major ‘hubs’ in 
the networks are also the same and include IL-1ra, IP-10, MCP-1, IL-6, IL-8, 
IFN-γ and TNF-α. The striking difference between the two networks is the 
difference in concentration of IL-2, which is downstream from IL-1β. In preterm 
labour it is noted that IL-1β causes a low concentration of IL-2 to be present 
which in turn causes a low concentration of IFN-γ and TNF-α.
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4.4.6 Support Vector Mechanisms 
The first analysis performed was on all 27 cytokines and gave a 5-fold cross 
validation accuracy of 63.75%. This means that the panel of cytokines decided 
whether a woman delivered preterm correctly 63.75% of the time. It also ranked 
the cytokines as to their importance in making the decision. Figure  4.7 shows 
the ranking of all 27 cytokines revealing IL-6 and IL-4 to be very important in the 
decision.  
 
Figure ‎4.7 Ranking of 27 cytokines 
 
These results may help to form a panel of biomarkers that may be used to 
predict if a woman is at risk of preterm birth. Clearly, 27 markers is a large 
number and so the next step was to reduce the number of cytokines to see if it 
improved or worsened the accuracy. A 10 cytokine classifier was done and 
gave a 5-fold cross validation accuracy of 65%. Interestingly, the most important 
cytokine was IL-4 but this time IL-6 was not as relevant (Figure  4.8) 
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Figure ‎4.8 Ranking of 10 cytokines 
 
 
To try and improve the accuracy further, the least relevant cytokines were 
removed and the process was repeated with only the two and five most relevant 
cytokines. With just two cytokine markers (IL-4 and IFN-γ) a 5-fold cross 
validation accuracy of 68.75% was gained.  
 
With five cytokines, adding in IL-6, IL-17α, MIP-1α; a slightly improved accuracy 
of 71.25% was noted (Figure  4.9). Another observation was that IL-4 is slightly 
more important than IFN-γ but you do need both. In other words these two 
markers can do the job reasonably well on their own but it is more accurate with 
all five. This could lead further study into the five most relevant cytokines to 
allow the analysis of their role in preterm birth. They would obviously also 










The ultimate goal in predictor algorithm biomarker discovery is to identify 
disease-associated biomarkers that can be used in clinical practice. Currently, 
the most robust biomarker in the prediction of preterm birth is cervicovaginal 
fetal fibronectin (152). However, the most reliable results are on those women 
who already have symptoms of preterm labour. Unfortunately, this is often too 
late in the disease process to try to prevent preterm birth from happening. Using 
biological samples taken at twenty weeks gestation, prior to the onset of clinical 
symptoms and signs, would enable women who would be most at risk to be 
highlighted at an early stage of pregnancy. This would allow identification of 
those women who would benefit from enhanced antenatal care, in the form of 
specialist consultant review and possibly cervical scanning. The women most at 
risk could then be offered potential management strategies in the form of 
infection screening, progesterone treatment or cervical cerclage. 
 
By studying a panel of twenty-seven cytokines I was able to ascertain any 
differences in plasma cytokine levels between women who had a preterm birth 
less than 35 weeks gestation and those who went on to have a term delivery. 
This study demonstrated that none of the cytokines tested showed any 
significant differences between those women who delivered preterm and those 
delivered at term. These findings agree with those of the systematic review by 
Conde-Agudelo et al. (173). They reported that of the 72 studies reviewed, 
which evaluated a total of 18 novel plasma and/or serum biomarkers, none had 
good predictive accuracy. 
 
A similar study to this was reported in 2010 (364) which demonstrated a 
significant association of matrix metalloproteinase-9 with spontaneous preterm 
birth. The authors highlighted that this positive finding could have occurred by 
chance due to the number of cytokines studied. We did not analyse MMP-9, 
therefore are unable to confirm or refute this finding.  
 
The only comparison groups that had significant findings were spontaneous 
preterm birth with intact membranes when compared with women who delivered 
at term. There was an overall tendency for IL-4 to be lower in women who had a 
preterm birth and this is similar to other studies where IL-4 was significantly 
lower in amniotic fluid of women with clinical signs of intrauterine infection and 
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inflammation (365, 366) who went on to deliver preterm. The interleukin 4 (367) 
is a cytokine that induces differentiation of naive helper T cells (Th0 cells) to 
Th2 cells. It is closely related and has functions similar to Interleukin 13 and is a 
key regulator in humoral and adaptive immunity which could play a role in the 
inflammatory process of preterm birth. 
 
There was also a statistically significant level of granulocyte-colony stimulating 
factor (G-CSF) in women who delivered preterm. The results demonstrated a 
trend to lower levels in women who delivered preterm birth than those women 
who delivered at term. This is in contrast to Goldenberg et al (368) who found 
that G-CSF levels were elevated in asymptomatic pregnant women at 24-28 
weeks who went on to deliver <32 weeks. This was thought to provide evidence 
that early spontaneous preterm birth is associated with an inflammatory process 
that is identifiable by the presence of a cytokine in maternal plasma several 
weeks before an early spontaneous preterm birth. G-CSF (367) is a 
glycoprotein that stimulates the bone marrow to produce granulocytes and stem 
cells and release them into the bloodstream. G-CSF also stimulates the 
survival, proliferation, differentiation, and function of neutrophil precursors and 
mature neutrophils which may be important in preterm birth caused by infective 
processes. 
 
IL-7 and IL-13 were also lower in women who delivered preterm than in women 
who went on to have term delivery and this appears to be a novel finding as this 
has not been reported in published literature before. IL-7 (367) a hematopoietic 
growth factor secreted by stromal cells in the bone marrow and thymus. It is 
important for B and T cell development. IL-13 (367) is cytokine secreted by 
many cell types, but especially Th2 cells and is a mediator of allergic 
inflammation and disease. 
 
The most widely studied cytokines (IL-1β, IL-6 and IL-10) did not appear to play 
a major role in this cohort, which may be by chance or reflect the different 
populations studied. One of the reasons for this could be these and other 
cytokines do not exert their influence as individuals.  
 
When the 27 cytokines were studied using Bayesian network analysis it was 
identified that the key players were IL-1ra, IP-10, MCP-1, IL-6, IL-8, IFN-γ and 
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TNF-α. The majority of these were pro-inflammatory (Th1) which would be as 
expected. The interesting difference between the term and preterm birth 
networks was the difference in concentration of IL-2, which is downstream from 
IL-1β. In preterm labour it was noted that IL-1β caused a low concentration of 
IL-2 to be present which in turn caused a low concentration of IFN-γ and TNF-α. 
IL-2 has key functions in immune response and therefore may be of importance 
in the inflammatory process of preterm labour. Whilst this approach has clarified 
the nature of these interrelationships, it has also enabled identification of key 
cytokines and relationships that govern preterm labour. These interrelationships 
with surrounding nodes may therefore warrant further investigation in silico or 
as targets for interventive treatment in the future. 
 
This study has both strengths and limitations. The main strengths are the focus 
on the systemic cytokine response and prospective collection of maternal 
plasma before the onset of labour or rupture of membranes. Other strengths 
include a diverse study population, rigorous assessment of gestational age, 
restriction to spontaneous preterm birth and the separate characterisation of 
PPROM and preterm labour, Despite the large size of our biobank, the small 
number of spontaneous preterm birth (n=40) that was analysed provides low 
power to detect the differences.  
  
These results clearly need confirmation with other studies. Further research is 
necessary to understand the pathogenesis of preterm birth and to improve the 
prevention strategies we use. It may be that cytokine mediation is not present at 
this range in the systemic circulation and that studying local levels in amniotic 
fluid or cervical mucus may have a clearer result. However, cytokines that are 
important in the preterm birth pathway have been identified and to progress and 










5 General Discussion and Future Work 
Preterm birth is a global issue affecting approximately 12.9 million births 
worldwide each year (1). Preventative strategies need good prediction tools in 
order to highlight the women most in need of care. One of the main difficulties 
when researching spontaneous preterm birth is the lack of uniform definition, 
with some reports defining it as less than 37 weeks, others less than 34 weeks 
or even less than 32 weeks. Some studies also report the differences of 
whether membranes have ruptured or not. Therefore given the heterogeneous 
pathophysiology of the condition, the limited clinical utility of any individual 
biomarker for predicting preterm birth is understandable. Also, even with the 
same patterns of preterm birth, it appears that biomarkers will perform 
differently across different ethnic populations and/or geographical locations. It 
may be that a multiple-marker test based on a combination of clinical and 
biological markers may be a more reliable predictor. An example of one that has 
been previously proposed is the five marker test (cervicovaginal fetal 
fibronectin, cervical length and serum alpha fetoprotein, G-CSF, and defensins 
or alkaline phosphatase) evaluated by Goldenberg et al. in the Preterm 
Prediction Study (86). The combined markers showed better predictive 
accuracy than when used alone. In addition, the overlap of the markers was 
small, supporting the notion that there are several different heterogeneous 
pathways that lead to spontaneous preterm birth. 
 
The overall aim of this study was to develop a predictive tool using both clinical 
data and plasma markers to try and detect those women at greatest risk of 
preterm birth. The cohort used was a nulliparous, low risk population, meaning 
the most pertinent risk factor of previous preterm birth was not included. These 
are women who in routine clinical practice we would have no other means of 
identifying those that will later deliver preterm. A test which would allow a 
proportion of these women to be identified as high risk in mid gestation would 
allow a targeted programme of cervical surveillance and the potential for 
prophylactic treatments such as progesterone or cerclage. 
 
The clinical risk factor algorithm provided a modest predictive performance for 
spontaneous preterm birth in this nulliparous, low risk population. The most 
clinically relevant group, those delivering less than 34 weeks, exhibited the best 
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predictive performance, with an area under the ROC curve of 0.74. Like most 
predictive tools for spontaneous preterm birth, this showed an excellent 
negative predictive value of 99%, due to the fact that most women delivered at 
term. However, its positive prediction would only have highlighted 33% of the 
births less than 34 weeks meaning we would still miss a significant proportion. 
Due to the study’s prospective design, cohort size, comprehensive range of 
candidate predictors, high quality data, and completeness to follow-up, the 
derived algorithms are likely to be indicative of the best performance achievable 
using clinical data to predict preterm birth in a healthy nulliparous population. 
The clinical risk tool performs to a similar standard when compared to more 
traditional scoring systems such as the Creasy score (144), however, as this 
tool does not require the history of a previous preterm birth, it has the added 
benefit of also being suitable for nulliparous women. As only 5% of women from 
this cohort delivered preterm, this still provided a better prediction than current 
clinical prediction from patient history. 
 
Clinical risk estimates for disease are already established in other areas of 
medicine and biomarkers are often added to improve performance. By using 
plasma proteomics I sought a biomarker which might improve the sensitivity of 
the clinical risk factor algorithm. However, proteomics being relatively new and 
emerging technology, I was unable to enter the depth of the proteome to 
discover low abundance proteins of interest. The proteins that were discovered 
appeared to be mainly plasma proteins related to systemic inflammation and 
therefore would not be specific enough for a marker for spontaneous preterm 
birth. 
 
Following on from this, I used a more targeted approach, using Luminex 
technology, to try to reach these lower abundance proteins. Cytokines are 
inflammatory mediators and have been frequently measured in cervicovaginal 
secretions and amniotic fluid of women who deliver preterm. It has been 
proposed that ascending infection leads to activation of inflammatory pathways 
which precede cervical shortening (369). This study was unable to detect a 
single cytokine in maternal plasma sensitive enough to be a marker for women 
who develop preterm labour. It did however highlight a group of cytokines that 
may be most relevant. A panel of five cytokines IL-4, IFN-γ, IL-6, IL-17α and 
MIP-1α appeared to be the most sensitive with a predictive accuracy of 71.25%. 
These cytokines should be analysed further to validate these findings. Another 
interesting result was the analysis of cytokines as a network to compare the 
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differences between term and preterm birth. This will allow a better 
understanding of the pathways and also provide further areas to explore in the 
investigation of predicting preterm birth. 
 
The use of cervical scanning and progesterone to reduce preterm births do 
appear to have a positive effect in reducing preterm birth and so is seems the 
importance of prematurity clinics to provide this surveillance remains crucial. It 
still remains difficult to highlight those women with no previous history who may 
benefit form this treatment. 
 
The biobank showed that almost 5% of the low risk women in the SCOPE 
population will deliver preterm. It therefore means that further research is 
needed into this important group of women to prevent further the problems of 
preterm birth. Sample collection was deliberately done at 20 weeks gestation as 
this is a common time when patients are reviewed in hospital for their fetal 
anomaly scan and so access for the blood sample was easy. Also, if a 
predictive tool was developed it would still allow time for a cervical scan to be 
preformed at a good time to allow chance of progesterone or cerclage to still 
have effect. It is also late on in pregnancy to be able to try to pick up changes 
already happening which could predispose women to deliver preterm. If a 
sample was taken too early, the inflammatory changes we expect to be 
happening may not yet be detectable in the blood. 
 
Leading on from my study there are a range of further research questions to be 
addressed. These can only be answered by the use of high quality, international 
data which will only be attained with the use of collaboration internationally to 
set up biobanks. One of the weaknesses of the SCOPE cohort is the very small 
numbers of very early preterm births. The only way to move forward in the quest 
to reduce preterm birth is to understand the different aetiologies better and to 
work together globally in the search for predictive and preventative strategies. 
One of the common pit falls of researching predicting spontaneous preterm birth 
is the assumption that prematurity is all the same. A large international biobank 
would allows us to increase the number of cases along with separating out the 
different phenotypes of preterm birth as it is very likely that different biomarkers 




Along with improving the numbers and types of cases we need to be more 
sophisticated with the analysis of data. New omic technologies have enabled us 
to examine a number of different biological samples in very sophisticated 
techniques; however, this has to be supported by the accurate analysis of data. 
Bioinformatics is having a promising renaissance and so it is important to be 
part of this future.  
 
I believe that with improvements in discovery techniques along with intelligent 
analysis of data we may be able to identify a panel of biomarkers for each 
preterm birth phenotype. This will allow us to highlight women at risk of preterm 
birth in the mid trimester enabling them to access a screening programme and 
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7 List of Abbreviations 
17P  17-alpha hydroxyprogesterone caproate 
ACTH  Adrenocorticotropic hormone 
AF  Amniotic fluid 
AmBic  Ammonium bicarbonate 
AMBP  Alpha-1-microglobulin/bikunin precursor 
ANOVA Analysis of variance 
AUC  Area under the curve 
BMI  Body mass index 
BV  Bacterial vaginosis 
CI  Confidence interval 
CL  Cervical length 
CRH  Corticotrophin-releasing hormone 
DES  Diethylstilbestrol 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
fFN  Fetal fibronectin 
FGF  Fibroblast growth factor  
GA  Gestational age 
G-CSF Granulocyte colony-stimulating factor 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HIV  Human immunodeficiency virus 
HPA  Hypothalamic-pituitary-adrenal 
HPLC  High performance liquid chromatography 
IgA  Immunoglobulin A 
IFN-γ  Interferon gamma 
IGFBP-1 Insulin-like growth factor binding protein-1 
IgG  Immunoglobulin G 
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IL-1  Interleukin-1 
IL-1β  Interleukin-1 beta 
IL-1ra  Interleukin-1 receptor antagonist 
IL-2  Interleukin-2 
IL-4  Interleukin-4 
IL-5  Interleukin-5 
IL-6  Interleukin-6 
IL-7  Interleukin-7 
IL-8  Interleukin-8 
IL-9  Interleukin-9 
IL-10  Interleukin-10 
IL-12p70 Interleukin-12 (p70) 
IL-13  Interleukin-13 
IL-15  Interleukin-15 
IL-17A Interleukin-17A 
IP-10  Interferon gamma-induced protein 10 
iTRAQ Isobaric tags for relative and absolute quantification 
IVH  Intraventricular haemorrhage 
kDa  Kilodalton 
LC  Liquid chromatography 
LC-MS Liquid chromatography-mass spectrometry 
LEEP  Loop electrocautery excision procedure 
LLETZ Large loop excision of the transformation zone 
LMP  Last menstrual period 
LSD  Lysergic acid diethylamide 
MARS  Multiple affinity removal column 
MCP-1 Monocyte Chemoattractant Protein-1 
MFI  Median fluorescence intensity 
MIP-1α Monocyte Chemoattractant Protein-1 alpha 
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MIP-1β Monocyte Chemoattractant Protein-1 beta 
MMP-9 Matrix metallopeptidase 9 
mRP  Macroporous reverse phase 
MS  Mass spectrometer 
NEC  Necrotising enterocolitis 
NO  Nitric oxide 
NPV  Negative predictive value 
OR  Odds ratio 
PBS  Phosphate-buffered saline 
PDA  Patent ductus arteriosus 
PDGF  Platelet derived growth factor  
PE  Phycoerythrin 
pHIGFBP-1 Phosphorylated insulin-like growth factor binding protein-1 
PlGF  Placental growth factor  
PM  Proteominer beads 
PP13  Placental protein 13 
PPROM Preterm prelabour rupture of membranes 
PPV  Positive predictive value 
PTB  Preterm birth 
PTB-IM Preterm birth with intact membranes 
PTB-PPROM Preterm birth with prelabour rupture of membranes 
PTL  Preterm labour 
PVL  Periventricular leukomalacia 
QTOF  Quadrupole-time-of-flight 
RDS  Respiratory Distress Syndrome 
RI  Resistance index 
ROC  Receiver operating characteristic 
RP  Reverse phase 




SCOPE Screening for pregnancy endpoints 
sd  Standard deviation 
SDS  Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sens  Sensitivity 
SES  Socioeconomic status 
SGA  Small for gestational age 
Spec  Specificity 
sPTB  Spontaneous preterm birth 
sPTD  Spontaneous preterm delivery 
SVM  Support vector machines 
RR  Relative risk 
RPM  Revolutions per minute 
TEAB  Triethylammonium bicarbonate 
TFA  Trifluoroacetic acid 
TNF  Tumour necrosis factor 
TVS  Transvaginal scan 
UK  United Kingdom 
USA   United States of America 
UV  Ultraviolet 
VEGF  Vascular endothelial growth factor 





Appendix A Proteins identified following depletion with MARS 14 and 
ProteoMinerTM Beads 
MARS 14 Column  ProteoMinerTM Beads  
Ceruloplasmin   Apolipoprotein A-I   
Complement C4-B   Fibrinogen alpha chain   
Inter-alpha-trypsin inhibitor heavy chain H4   Fibrinogen beta chain   
Hemopexin   Apolipoprotein A-IV   
Apolipoprotein A-IV   Clusterin   
Antithrombin-III   Serum albumin   
Inter-alpha-trypsin inhibitor heavy chain H1   Vitronectin   
Inter-alpha-trypsin inhibitor heavy chain H2   Serum paraoxonase/arylesterase 1   
Alpha-1B-glycoprotein   Fibrinogen gamma chain   
Vitamin D-binding protein   Complement C4-A   
Alpha-1-antichymotrypsin   Inter-alpha-trypsin inhibitor heavy chain H4   
Vitronectin   Complement C1r subcomponent   
Clusterin   Ig mu chain C region   
Alpha-2-HS-glycoprotein   Ig gamma-1 chain C region   
Keratin, type II cytoskeletal 2 epidermal   Prothrombin   
Complement factor B   Apolipoprotein E   
Prothrombin   Ig gamma-3 chain C region   
Complement component C9   Hemopexin   
Heparin cofactor 2   Ceruloplasmin   
Complement factor H   Plasminogen   
Inter-alpha-trypsin inhibitor heavy chain H3   Ig kappa chain C region   
Keratin, type I cytoskeletal 10   Apolipoprotein C-III   
Sex hormone-binding globulin   Complement C1q subcomponent subunit B   
Serum amyloid P-component   Alpha-2-HS-glycoprotein   
Plasminogen   Alpha-1-antichymotrypsin   
Complement C1s subcomponent   Ig gamma-2 chain C region   
Leucine-rich alpha-2-glycoprotein   Ig gamma-4 chain C region   
Kininogen-1   C4b-binding protein alpha chain   
Keratin, type II cytoskeletal 1   Complement C1s subcomponent   
Complement C1r subcomponent   Complement C1q subcomponent subunit C   
Gelsolin   Apolipoprotein D   
Lumican   Transthyretin   
Serum paraoxonase/arylesterase 1   Inter-alpha-trypsin inhibitor heavy chain H1   
Fibrinogen alpha chain   Pregnancy-specific beta-1-glycoprotein 4   
C4b-binding protein alpha chain   Apolipoprotein C-I   
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Complement C1q subcomponent subunit C   Vitamin K-dependent protein S   
Complement component C8 alpha chain   Antithrombin-III   
Fibrinogen beta chain   Ig lambda chain C regions   
Carboxypeptidase N catalytic chain   Vitamin D-binding protein   
Complement component C8 beta chain   Ig kappa chain V-III region SIE   
Complement component C8 gamma chain   Pregnancy-specific beta-1-glycoprotein 3   
Complement factor I   Keratin, type II cytoskeletal 1   
Afamin   Inter-alpha-trypsin inhibitor heavy chain H2   
Pregnancy-specific beta-1-glycoprotein 1   Ig alpha-1 chain C region   
Protein AMBP   Apolipoprotein C-II   
Pregnancy-specific beta-1-glycoprotein 6   Sex hormone-binding globulin   
Complement C1q subcomponent subunit B   Complement C3   
Coagulation factor XII   Heparin cofactor 2   
Pregnancy-specific beta-1-glycoprotein 9   Alpha-1-antitrypsin   
Fibrinogen gamma chain   Alpha-1B-glycoprotein   
Apolipoprotein C-III   Haptoglobin   
Fetuin-B   Serum amyloid A-4 protein   
Complement C1r subcomponent-like protein   Fibrinogen-like protein 1   
Keratin, type II cytoskeletal 5   Serotransferrin   
Kallistatin   Apolipoprotein A-II   
Complement component C7   Lipopolysaccharide-binding protein   
N-acetylmuramoyl-L-alanine amidase   Sulfhydryl oxidase 1   
Complement component C6   Kininogen-1   
Glutathione peroxidase 3   Complement factor B   
Vitamin K-dependent protein S   C4b-binding protein beta chain   
Alpha-1-antitrypsin   Hemoglobin subunit beta   
Complement C2   Ig kappa chain V-IV region Len   
Keratin, type II cytoskeletal 1b   Complement factor H   
Retinol-binding protein 4   Afamin   
Keratin, type I cytoskeletal 9   Ig kappa chain V-II region RPMI 6410   
Apolipoprotein C-I   Histidine-rich glycoprotein   
Histidine-rich glycoprotein   Coagulation factor XII   
Apolipoprotein C-II   E3 ubiquitin-protein ligase TRIM33   
Carboxypeptidase B2   Tsukushin   
Coagulation factor IX   Apolipoprotein F   
Ficolin-3   Fibulin-1   
Plasma kallikrein   Coagulation factor V   
Attractin   Keratin, type I cytoskeletal 10   
Keratin, type I cytoskeletal 27   C-reactive protein   
Serum amyloid A-4 protein   Protein S100-A9   
C-reactive protein   Gelsolin   
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Monocyte differentiation antigen CD14   Apolipoprotein C-IV   
Alpha-2-antiplasmin   Collectin-11   
Fibulin-1   Alpha-2-antiplasmin   
Carbonic anhydrase 1   Protein FAM59B   
Apolipoprotein E   Fetuin-B   
Apolipoprotein C-IV   Complement factor I   
Beta-2-glycoprotein 1   Hyaluronan-binding protein 2   
Adiponectin   Complement component C9   
Complement C5   Histone-lysine N-methyltransferase SUV39H1   
Hyaluronan-binding protein 2    
Mannan-binding lectin serine protease 1    
Apolipoprotein M    
Fibronectin    
Adenylate cyclase type 10    
Mannose-binding protein C    
Dopamine beta-hydroxylase    
Thyroxine-binding globulin    




Appendix B Following MS/MS of the iTRAQ labeled plasma, 243 high confidence proteins were identified with relative 
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Vitronectin  98 1.13 0.20 1.06 0.30 1.09 0.37 1.04 0.40 1.22 0.44 
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Insulin-like growth factor II  11 0.89 0.40 0.89 0.33 0.79 0.15 0.89 0.28 1.06 0.71 
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Serum amyloid P-component  9 0.86 0.66 0.87 0.52 0.85 0.60 0.97 0.91 0.97 0.90 
























Complement factor H-related 
protein 5  









Intercellular adhesion molecule 
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Cell surface glycoprotein 
MUC18  











































Neural cell adhesion molecule 
L1-like protein  


























subcomponent subunit A  
12 0.75 0.45 1.05 0.77 0.77 0.28 0.92 0.62 0.52 0.19 
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